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ADRIA L. BYKOWSKI. A novel method for the production of potentially therapeutic 
human monoclonal antibodies in vitro. (Under the direction of Dr. Natalie Sutkowski). 
We have developed a novel approach for the production of potentially therapeutic 
human monoclonal antibodies in vitro. This method holds great promise for generating 
therapeutic antibodies against infectious disease, cancer, and inflammation. The complex 
nature of current methods for producing human monoclonal antibodies is a major 
impediment to large scale passive transfer immunotherapy. Our novel technique utilizes 
Epstein-Barr virus immortalized tonsil or peripheral blood B cells from healthy human 
volunteers. These B cells are forced to undergo non-specific differentiation to become 
mature IgG antibody producing plasma "like" cells that continuously proliferate in vitro. 
U sing this method, millions of transformed B cells can be generated and screened for 
production of antibodies of desired specificity. Optimization of EBV infection, reaching 
nearly 100%, was achieved by combining viral concentration, using centrifugal 
ultrafiltration with "spinfection". Thisallowed for transformation of the largest possible B 
cell repertoire from human tonsil samples, a rich source of B cells. EBV immortalized 
tonsil B cells were forced to undergo differentiation into IgG secreting plasma "like" 
cells through addition of anti-Igm (Fab')2, Interleukin (lL)-4 and IL-6 or anti-IgM 
(Fab'h, soluble CD40L and BAFF once a week for three weeks. We hypothesized that 
anti-IgM (Fab')2 would mimic antigen activation of the BCR and CD40L would mimic T 
cell costimulation. ELISA analysis of supernatants from the immortalized cells indicated 
that we efficiently induced immunoglobulin isotype class switching from IgM to IgG 
after several weeks, and that the transformed B cells continued to secrete IgG for months 
in vitro. Flow cytometry analysis revealed that IgG secreting immortalized B cells have a 
XlI 
differentiated surface expression phenotype that resembles plasma cells. We are currently 
applying this differentiation method to produce therapeutic and diagnostic antibodies 
against avian influenza virus hemagglutinin (H5 HA). EBV immortalized tonsil and 
peripheral blood B cells produced IgG antibodies specific for H5 HA. Overall, the results 
indicate that differentiation of immortalized human B cells can be influenced in vitro, 
with the ultimate purpose of exploiting their therapeutic potential. 
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Chapter 1: Background and Introduction 
Human immune system 
The immune system IS a collection of cells and secreted factors within an 
organism that protects against infection by identifying and killing pathogens [1]. The 
immune system protects the body from harmful substances by recognizing and 
responding to antigens [2, 3]. Antigens are structural portions of molecules on the surface 
of cells, viruses, fungi, or bacteria as well as non-living substances such as toxins, 
chemicals, drugs, and foreign particles, which are recognized by the immune system. 
Immune detection is complicated because pathogens adapt and evolve new ways to 
successfully infect the host organism and evade immune detection, e.g. some viruses 
have a very high mutation rate [2]. First-time exposure to pathogens like viruses and/or 
bacteria sometimes triggers an immediate innate immune response, which is followed by 
the robust adaptive response [3]. 
Microorganisms that successfully enter a host will immediately encounter the 
innate immune system. Innate immune defenses are considered non-specific, meaning 
these systems recognize and respond to pathogens in a general way, usually through 
pattern recognition [5, 6]. The innate immune system does not confer long-lasting 
immunity against a pathogen; however, it is an effective first line of organism defense 
[4]. The innate response consists of chemical barriers, inflammation and specialized cells 
that respond to infection [5]. Inflammation is the result of cytokines which are released 
by injured or infected cells as well as T cells (part of the adaptive immune response) [1]. 
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These secreted chemicals raise the temperature in the affected area and recruit leukocytes 
to the site of infection to promote removal of the pathogen as well as healing of any 
damaged tissue [5]. 
Cytokines and complement are the major components of the innate immune 
response. The complement system consists of over 20 proteins in the serum [5, 9, 10], 
which work by attacking the surfaces of foreign cells. Complement can cause lysis of 
foreign cells through different mechanisms including complement dependent cell 
cytotoxicity (CDCC), and formation of the complement membrane attack complex (MAC 
complex) [6]. 
The innate immune response utilizes many soluble and cellular forms of defense 
to identify pathogens through pattern recognition, activating toll-like receptors (TLR) and 
other receptors [12, 13]. Innate immunity can eliminate pathogens, by attacking them I 
through direct cellular contact, by engulfing and killing microorganisms or through 
activating adaptive immune cells [7]. The innate immune system has an important role in 
mediating the activation of the adaptive immune system by promoting presentation of 
antigenic peptides and through secretion of cytokines [5]. 
The adaptive immune system allows for both a robust antigen-specific immune 
response as well as immune memory, and is restricted to certain cell types. Memory is 
defined by a subset of cells that are specific for a pathogen and respond quickly upon re-
exposure [8]. The adaptive immune response is specialized for individual pathogens [16, 
17], and is maintained by "memory cells" (two subsets; Band T cells) [9]. If a pathogen 
infects the body twice or more, specific memory cells quickly eliminate the invader. 
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The adaptive immune response involves the activities of many cells known as 
lymphocytes or white blood cells. B cells and T cells are the two major categories of 
lymphocyte; they perform different tasks in the adaptive immune response [6, 9]. Both B 
cells and T cells express receptors that recognize particular antigens (portions of 
molecules that stimulate an immune response; there can be many antigens for one 
pathogen). Lymphocyte activation results in memory responses [6, 10]. While they have 
similar antigen receptors, Band T cells are very different. B cells are involved in the 
humoral immune response (antibody production), whereas T cells are involved in cell-
mediated immune responses. 
Cytotoxic T and helper T cells are major players in the adaptive immune 
response, while natural killer T cells have a role in the innate. There are two major 
subtypes of T cells involved in the adaptive immune response: cytotoxic (mainly CD8+) 
and helper T (mainly CD4+) cells. Cytotoxic T cells cause direct lysis of pathogens and 
infected cells, while helper T cells secrete cytokines and growth factors to amplify the 
immune response [11]. Both types express T cell receptors (TCR) and recognize antigen 
in the context of the major histocompatibility complex, (MHC) class I or class II 
molecules [12]. MHC restriction means that T cells only recognize antigenic peptides 
presented on MHC molecules [12]. MHC restricted cells cannot recognize antigens that 
are unprocessed or not presented on MHC. Cytotoxic T cells mainly recognize antigenic 
peptides expressed on Class I MHC molecules, which is expressed on all cells, and cause 
direct lysis of infected targets [11,20,21] (Figure 1.1). Helper T cells mainly recognize 
antigenic peptides presented on Class II MHC molecules, which are expressed on 
macrophages, dendritic cells and B cells, resulting in secretion of cytokines and growth 
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factors that help other immune cells to fight infection (Figure 1.1) [13]. The distinct 
responses mounted by T cells reflect the different roles the two types of T cells play in 




Figure 1.1. Helper T (CD4+) and cytotoxic T (CDS+) cell interactions with MHC and 
antigenic peptide on an antigen presenting cell. Helper T cells are activated by 
interaction with antigenic peptide in the context of MHC II. These activated cells then 
secrete cytokines that enhance the immune response to the antigen. Cytotoxic T cells are 
activated through interaction with antigenic peptide in the context of MHC I molecules. 
The activation of these cells leads to direct killing of the cell presenting antigenic 
peptides. Both types of T cells require a secondary costimulatory signal for activation, 
which is received through CD28, and other costimulatory molecules. 
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B cell immunology 
Analogous to the T cell receptor on T cells, B cells express a specific 
immunoglobulin (lg) on the cell surface which is known as the B cell receptor (BCR) [6]. 
NaIve mature B cells express both IgM and IgD molecules on the cell surface until 
activation, at which point IgM becomes dominant. The B cell receptor on naIve cells is an 
unmutated IgM antibody molecule, which is bound to the cell surface [6]. The B cell 
receptor can recognize antigens on whole pathogens without any need for processing or 
MHC presentation. Each B cell expresses a unique antibody, with estimates of 
approximately 107 different antigen specificities possible [23, 24]. When B cells are 
activated by specific antigens, the membrane bound immunoglobulin is converted to a 
secreted form [14]. T cell help causes antigen activated B cells to differentiate. This 
results in immunoglobulin isotype class switching, antibody secretion, and the production 
of memory B cells. Ig isotype class switching IS a process that causes secreted 
immunoglobulin changes from IgM to IgG, IgE or IgA [24, 25]. These secondary 
immunoglobulin isotypes then undergo the process of somatic hypermutation of the 
variable region, which results in affinity maturation i.e. secretion of antibodies that bind 
the antigen better than their unmutated counterpart. The secreted antibodies can bind 
antigens, and lead to complement activation, neutralization and/or engulfment of 
pathogens [6]. Antibodies have two major portions, the constant region (Fc), which 




B cells are key players in the adaptive immune response because they amplify the 
immune response to pathogens and secrete antibodies to specific antigens. When antigen 
interacts with the BCR on a naYve B cell, the antibody/antigen complex is internalized, 
processed into peptides in the endosomes and presented on MHC class II molecules to 
helper T cells [15]. The T cells provide secondary costimulatory signals that like CD40L, 
the naYve B cells require for activation. T cells also secrete cytokines and growth factors, 
that lead to B cell activation and maturation [6]. 
B cell differentiation 
B cells can respond to T cell dependent antigens or T cell independent antigens 
[16]. T cell dependent antigens require T cell help through costimulatory signals for B 
cell activation [28, 29]. T cell independent antigens, like bacterial polysaccharides, can 
directly induce B cells to produce antibodies in the absence of T cells [6, 17]. Once 
activated, a blasting B cell undergoes cell division and begins to differentiate in the 
specialized microenvironment of the germinal center in peripheral lymphoid organs [17]. 
Germinal centers are formed within a week of antigen stimulation. Antigen activated B 
cells can follow two fates, either differentiation into plasma cells or into memory cells 
[6]. Plasma cells are terminally differentiated B cells. They secrete high amounts of 
monoclonal antibodies specific to the antigen that induced the B cell activation (Figure 
1.2). Memory B cells circulate and remain dormant until secondary encounter with 
antigen, at which point they secrete affinity matured Ig [18]. In the germinal center Ig 
isotype class switching occurs in antigen activated B cells in response to T cell secreted 
cytokines [19]. Cytokines induce isotype class switching by activating the switch 
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recombination sites that lie 5' to each CH gene [6]. Affinity maturation is the gradual 
increase in the affinity of antibodies for a specific antigen, and is a consequence of 
somatic hypermutation of the immunoglobulin genes [18]. B cells that have the highest 
affinity for antigen are given survival signals during antigen presentation by follicular 
dendritic cells, while lower affinity antibody producing cells do not recibed the survival 
signals and are not expanded. This process is known as clonal selection [6]. The germinal 
center B cells differentiate into to memory B cells or plasma cells, which exit the lymph 
node and enter the periphery. 
The B cell response to a pathogen during the first exposure is slow, taking more 
than seven days to mount a robust response that clears the infection. During this time, 
naive B cells differentiate into antibody secreting cells, resulting in antigen specific 
clonal expansion, and memory is established (Figure 1.3) [6]. The memory B cells 
provide long-lasting protection against re-infection with the same pathogen, and clear the 
infection within a few days, when the pathogen is encountered again (Figure 1.3). The 
activation and differentiation of a B cell results in immunoglobulin class switching from 
IgM antibody, produced by naIve B cells, to higher affinity IgG, IgA or IgE antibody, 
which is produced by immunized or memory B cells. Immunization results in rapid 
production of affinity matured Ig. A slow primary response could be dangerous to the 
















Figure 1.2. Antigen dependent B cell differentiation. Antigen binds to the B cell 
receptor (purple) on naIve B cells. The antigen is then processed and presented to helper 
T cells on MHC II molecules. The B cell blasts express activation markers like ICAM 
and CD23. With T cell help, B cells differentiate into germinal center B cells where Ig 
isotype class switching and affinity maturation take place. Memory B cells and plasma 
cells are then released into the periphery where they secrete antigen-specific IgG 



































Figure 1.3. Specific memory by B cells increases immune response and shortens 
reaction time to pathogens. The adaptive immune response to a primary pathogen 
occurs slowly over several days and the antibody response is limited. However, upon re-
exposure, the memory cells mount a robust adaptive immune response immediately. 
Terminally differentiated (plasma) B cells secrete antibodies that circulate in 
blood, plasma and lymph, binding to specific antigens, pathogens, or virus infected cells 
[35, 36] marking them for destruction through complement activation, and phagocytosis 
(Figure 1.4). Antibodies can also neutralize pathogens directly, by binding to bacterial 
toxins or by interfering with receptors that pathogens use to infect cells [6]. These 
characteristics of antibodies make them effective against pathogens of many types. 
Therefore, novel and cost effective ways of producing human monoclonal antibodies 
could be of therapeutic value. 
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Figure 1.4. Role of antibodies in the immune defense against tumors and pathogens. 
Antibodies are produced by B lymphocytes in response to infections and cancer. 
Antibodies have two regions~ a constant region that is recognized by Fc receptors on 
other immune cells, and a variable region that is specific for antigen. Antibodies 
neutralize pathogens and cause lysis of infected cells and tumor cells, making them very 
desirable for vaccine use and anti-tumor therapy. 
10 
Epstein - Barr virus (EBV) 
More than 900/0 of the adult population is latently infected with the common 
human herpesvirus EBV. EBV is a double stranded DNA herpesvirus that encodes 
approximately 100 genes, and is the causative agent of infectious mononucleosis, a self-
limiting lymphoproliferative disease characterized by B cell expansion and extensive T 
cell activation [20]. EBV preferentially infects resting B lymphocytes, both naIve and 
memory B cell [21]. Cellular infection can be divided into lytic and latent stages. Lytic 
infection results in viral replication, while viral latency is associated with lifelong chronic 
infection [39, 40]. There are at least three forms of viral latency in B cells, which differ 
in the expression profile of EBV latent genes, and the corresponding differentiation stage 
of the infected B cell. The latency program comprise: (l)the growth program (also known 
as latency III), (2) the default program (latency II) and (3) the memory program (latency 
I) [22]. There are eight latent genes consisting of, EBV nuclear antigens (EBNAs) 1-6 
and latent membrane proteins (LMPs) 1 and 2 [42-44]. 
Epstein-Barr virus is a tumor virus that is associated with several B cell 
malignancies, which correlate with the different latency programs. EBV related post-
transplant lymphoproliferative disease (PTLD) and AIDS related lymphomas arise during 
the growth program of latency (latency III: EBNA 1-6, LMPI, and LMP2) and the B cells 
resemble antigen activated B cells blasts. EBV related Hodgkin's lymphoma (HL) 
derives from germinal center B cells that have undergone isotype class switching and 
hypermutation, and express the default program of latency (latency II: EBNA 1, LMPI 
and LMP2) [45]. EBV positive Burkitt's lymphoma (BL) derive from post-germinal 
center or memory cells. They have characteristic chromosomal translocations between c-
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myc and the IgH enhancer, which are responsible for transformation; they express viral 
latency I program (EBNAI only) (Figure 1.6). It is not known why some people develop 
EBV associated B cell lymphomas, however tumors more commonly arise as a result of 
. . 
ImmunosuppressIon. 
EBV and B cell differentiation 
Epstein-Barr virus is known to infect naive B cells, and the reigning theory on 
infection is that it exploits the antigen dependant B cell differentiation pathway in order 
to obtain access in the memory B cell compartment, the site of long-term viral persistence 
[23]. EBV preferentially infects resting B cells by binding to CD21, and is internalized 
by receptor-mediated endocytosis. Epstein-Barr virus has a unique ability to transform B 
cells. EBV infection of B cells in vitro, results in indefinite growth [46, 47] and 
generation of lymphoblastoid cell lines (LCL). These cells divide in the absence of 
cytokines and antigen stimulation, which are normally required for proliferation (Figure 
1.5). The proliferation is dependent upon the expression of 9 latent genes including six 
nuclear proteins (EBNA 1, EBNA2, EBNA3a, EBNA3b, EBNA3c, EBNA-LP), three 
latent membrane proteins (LMPl, LMP2a, LMP2b) and two small RNAs (EBERS) [24]. 
The infected cells resemble antigen activated B cell blasts. Lymphoblastoid cells are 
growth selected and the growth is dependent upon EBNA2 and LMP 1. Cells that lose 
EBNA2 expression subsequently stop dividing (Figure 1.5) [49-51]. 
In contrast, in vivo, EBV infected blasting B cells differentiate, and sequentially 
loses nearly all viral gene expression. Once EBV gains access to the memory B cell 
compartment, the virus is thought to evade detection by the immune system by residing 
in resting cells that express limited viral genes (mainly EBNA 1, which is responsible for 
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episomal maintenance) [40, 46, 52, 53]. Virus infected memory B cells reactivate when 
they bind antigen, which triggers plasma cell differentiation. Lytic viral replication is 
triggered by plasma cell specific gene expression [25]. The role that EBV plays in B cell 
differentiation is unclear; however, viral gene expression at each stage has been 
elucidated based upon the EBV tumors that arise. 
Antigen dependent B cell differentiation occurs in the lymph node, and likely 
requires antigen and T cell derived help in the form of cytokines and costimulation. It is 
thought that the viral oncoproteins LMPI and LMP2 may partially supply B cell 
differentiation signals leading to germinal center formation. LMPI and LMP2 are 
functional viral homologs of constitutively active cellular CD40 and the B cell receptor, 
respectively [55-58]. LMPI transcription factor NF-lCB, which promotes B cell growth 
and differentiation, leading to uncontrolled B cell growth [57, 59]. Germinal center B 
cells lose expression of EBNA2, which is a key transactivtor of other latent genes, and 
express the default or latency II program of viral genes, EBNA1, LMPI and LMP2. 
Further differentiation to memory B cells results in loss of LMP expression, and the exit 
of latency I program cells (EBNAI only) from the lymph node into the periphery [26]. 
Memory cells are the long-term viral reservoir in which, the virus remains dormant, and 
essentially hidden from the host immune system, until subsequent reactivation through 
antigen/BCR interaction.' Activated memory cells become plasma cells that induce the 
lytic cycle, leading to virus production, and de novo infection [54, 61, 62]. Disruption of 
the tightly regulated surveillance of EBV infected cells can lead to EBV associated 



























Figure 1.5. Epstein-Barr virus infection of B cells differs in vitro and in vivo. In vitro 
EBV causes B cells to blast, and maintains them in this state indefinitely. In vivo EBV 
infects naive B cells and causes them to blast, like antigen. As the B cells differentiate 
they lose the expression of the EBNAs, and express the LMPs, which mimic antigen 
activation and T cell help. The B cells can differentiate into memory cells where EBV 
persists or into plasma cells where viral replication occurs. Therefore, it is proposed that 
EBV exploits the antigen dependent B cell differentiation pathway to gain access to the 
memory B cell compartment. 
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Monoclonal antibodies 
Current monoclonal antibody (mAb) therapy: a vaccine alternative 
Classic vaccinations work by activating the adaptive immune response and 
eliciting a strong IgG antibody response. These vaccinations are based on the injection of 
pathogen derived proteins in order to stimulate B cells to produce antibodies that bind to 
the specific proteins [27]. The aim is to elicit an immune response that clears the 
infection [11,64]. The antibody response to primary pathogen exposure slowly results in 
formation of memory B cells [6]. The robust response elicited by vaccination is a means 
of priming the immune system to attack the pathogen quickly upon subsequent exposure. 
IgG are proteins made by B cells that circulate in the blood and are a major line of 
defense [28]. Therapeutic monoclonal antibodies can confer passive protection against 
specific pathogens to the recipient; however, no memory is made to the antigen. 
Antibodies can be a safe and effective way to treat virulent viruses, tumors, and multi-
drug resistant bacterial strains. Several antibody therapies have been created for cancer 
treatments, inflammation and autoimmune diseases [29]. One example is Rituximab, an 
anti-CD20 antibody, effective against lymphomas; it acts through several mechanisms 
including complement activation and caspase activation [66-70]. There is a strong need 
to develop more therapeutic antibodies specific for tumor antigens for cancer treatment 
and infectious pathogens to fight infection, that are both reliable and cost effective. 
Avian influenza has caused three pandemics world wide in 1918, 1957 and 1968, 
killing over 50 million people. There are no good vaccine for avian influenza and current 
methods for producing influenza vaccines reI y on virus production in eggs, which is time 
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consLuning and not suffIcient for producing enough vaccine for the entire population [71-
74]. Passive in1munization is an alternative to vaccination, [30] because hUlnan 
1110noclonal antibodies can be adnlinistered before exposure to prevent illness. Therefore, 
novel and fast methods for the production of human (IgG) monoclonal antibodies could be 
considered as an alternative to classic vaccination for especially virulent pathogens. 
Current methods for the creation of human monoclonal antibodies 
Antibody therapy has proven efficacy in treating venonlOUS animal bites, certain 
cancers and infectious diseases as a vaccine alternative [65]. In the 1970s, antigen specific 
monoclonal antibodies were known to be therapeutically important but proved difficult to 
produce, which made them a target for additional research to develop an easier method for 
their production. At the time, it was known that mice could be exposed to antigens to 
create antigen specific plasma B cells, but there was no way to isolate and expand the 
plasma cells that produced the desired monoclonal antibodies. This made prolonged 
monoclonal antibody production impossible. The first successful attempt to isolate and 
expand plasma cells that produced antigen specific monoclonal antibodies was performed 
in 1975 by Kohler and Milstein [31]. They demonstrated that mouse myeloma cells could 
be fused with non-transformed spleen plasma cells from mice immunized against sheep red 
blood cells (SRBC), resulting in continuously proliferating cells that produced antibodies 
for several months in culture. These cells were fused by treatment with Sendai virus and 
grown in media that promoted growth of myeloma cells and hybridized spleen-myeloma 
cells. Kohler and Milstein found that the fusion of the two antibody-producing cells 
resulted in the expression of Ig from both cells, indicating that allelic exclusion did not 
occur in the resulting hybrid cell [31]. The Ig genes were randomly mixed in the hybrid but 
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showed no changes to the rearranged genes encoding the constant or variable regions of 
either cell. SRBC specific Sp-hybrid (spleen B cell and n1yelon1a hybrid) cells were 
identified through plaque formation in SRBC-containing soft agar. Individual SRBC-lysing 
hybrid clones were isolated and shown to retain expression of myelolna cell Ig as well the 
SRBC-specific Ig in culture. The isolation demonstrated that antigen specific monoclonal 
antibodies could be produced through cell fusion techniques [31]. The Sp-hybrid cells 
resulted in direct plaques, and plaque formation was inhibited with the addition of anti-IgM 
antibodies, which indicated that SRBC-specific IgM antibodies were primarily secreted by 
the hybrid cells. This method allowed for the isolation of hybrid cell lines that produced 
mouse antibodies directed against a specific antigen. 
The hybridoma technology work of Kohler and Milstein demonstrated that specific 
antibodies could be produced in culture, which led to several advances in antibody 
research, technology and treatment. One of the resulting advances allowed for the 
production of large quantities of monoclonal antibodies using both in vivo and in vitro 
methods. The procedure yields cell lines capable of producing one type of antibody protein 
for a long period. Hybridoma cells secreting monoclonal antibodies were produced by 
fusing human lymphocyte-derived myeloma cells with primary antibody-producing plasma 
cells from the spleen of an antigen challenged animal [76]. To facilitate the fusion, 
myeloma cells were cultured with 8-azaguanine one week prior to fusion to ensure their 
sensitivity to the hypoxanthine-aminopterin-thymidine (HAT) selection medium used for 
hybridoma selection. 8-azaguanine ensured sensitivity by inhibiting the normal pathway for 
nucleotide synthesis in the myeloma cells. Within the HAT medium, the inhibitor 
aminopterin ensured that only fused hybridoma cells survived, by blocking the synthetic 
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(de novo) path\vays through which nucleotides are nlade. In order for cells to survive, they 
needed to bypass the defective nucleic acid synthesis pathway of the nlyelonla cells. Since 
neither the nlyelonla nor the antibody-producing cells alone will grow in the selective 
Inedia, only the fused hybrid cells survived [76]. These cells divided and secreted anilllal-
derived monoclonal antibodies indefinitely in culture [32]. While good for research, the 
resulting animal-derived antibodies were incompatible with the human immune system 
yielding ineffective therapies and serum sickness [77, 78]. 
There are several techniques for creating human and non-human antibodies of 
certain specificity; however, with the change in technology comes change in procedures. 
Early therapeutic antibodies were created using gene technology, a technique where 
immunoglobulin variable (V) genes are amplified from hybridomas or B cells using 
polymerase chain reaction (peR) [79]. These variable genes are then cloned into 
expression vectors with soluble antibody fragments. The antibodies are then screened for 
binding affinity. This process is very time consuming and success rates for specific 
variable regions are low [33]. Screening of variable genes was revolutionized when the 
genes were expressed on phage. Complete antibody variable domains are displayed on the 
surface of fd bacteriophage. These phage bind specifically to antigen and can be isolated 
through affinity chromatography [24]. Affinity chromatography is time consuming, but 
this technique is still being used. 
Another method for human monoclonal antibody production is the use of 
genetically engineered mice. The major impediment to the development of murine 
monoclonal antibodies (mAbs) for therapy in humans has been reducing their potential 
immunogenicity. There have been several attempts to overcome this obstacle. One of 
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these methods is XenoMouse technology [34]. These humanized mice retain the ease of 
generating mAbs from a mouse without more cloning. XenoMouse strains carry portions 
of the human immunoglobulin heavy chain (lgH) and light chain loci (JgK) among other 
important human immunoglobulin genes. The transgenes were bred onto a strain of mice 
with immunoglobulin deficiency. The XenoMouse mice are immunized with antigens of 
interest, and mount an adaptive immune response, resulting in antigen-specific, fully 
human immunoglobulin. These monoclonal antibodies from XenoMouse mice exhibit 
therapeutic potential both in vitro and in vivo without serum sickness [34]. 
Human monoclonal antibodies have also been created from mouse antibodies 
through substitution of the complementarity-determining regions (CDR). This technique 
replaces mouse CDRs from the heavy-chain variable region of mouse antibody with the 
corresponding CDRs of a human myeloma protein [35]. CDR replacement offers a 
different way of constructing human monoclonal antibodies from corresponding mouse 
monoclonal antibodies. 
Recently, a new method for creating human monoclonal antibodies in vitro was 
reported. This method utilizes Epstein-Barr virus (EBV) and peripheral blood from 
volunteers that have been exposed to pathogens of interest. EBV was used to transform 
human memory B cells from donors that have recovered from severe acute respiratory 
syndrome coronavirus (SARS-CoV) infection and H5N 1 avian influenza virus [82, 83]. 
The obtained EBV infected memory B cells specific to the antigen of interest, which 
secreted monoclonal antibodies that had the ability to neutralize pathogens. This method 
demonstrates that EBV can be used to immortalize B cells and rapidly create human 
monoclonal antibodies, which can neutralize pathogens. The limitation of that is that the 
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B cells must come from a donor that has already cleared an infection. This method would 
not work for some highly lethal pathogens because the infected people would die prior to 
Ab production. Exposing a volunteer for antibody production is risky and un ethical. 
Pitfalls of current monoclonal antibodies technologies 
Current methods for the production of human monoclonal antibodies that have 
been discussed are time consuming and labor intensive. To date, the most successful 
approach for producing antibodies is the use of humanized mice that have been 
genetically engineered to secrete human immunoglobulin [34]. However, the availability 
of these mice has also hindered the mass production of antibodies, and they are typically 
reserved for diseases like cancer. The methods that involve isolating memory B cells 
from previously infected individuals are rapid and advantageous to the humanized mouse 
model because the immune system of the volunteer has already done all of the work to 
create human IgG specific to the antigen. However, this technology requires that the B 
cells be isolated from a volunteer that has recovered from pathogen exposure. Prior 
exposure and recovery from a pathogen leads to the problem of donor availability, 
particularly for deadly pathogens such as Ebola [36]. These constraints on current 
methods for the creation of monoclonal antibodies create a need for a novel technique of 
antibody production that is both cost effective and can be scaled up quickly. 
20 
Chapter 2: Rationale and Specific Aims 
Antibodies are an important component of the immune response to pathogens and are 
produced as a consequence of terminal B cell differentiation. Antibodies can neutralize 
pathogens and cause lysis of infected cells and tumor cells through ADCC. These 
qualities of antibodies make them desirable for pathogenic treatments and research needs. 
In particular monoclonal antibody therapy has shown great promise in cancer 
therapeutics (e.g. Rituximab) and is a very powerful alternative to conventional 
vaccination. While polyclonal antibodies work well in some instances, monoclonal 
antibodies are more desirable for therapeutic treatments [37]. However, the production of 
human monoclonal antibodies is technologically complex, and existing protocols involve 
their creation in humanized mice or by phage display technology, both with lengthy time 
to production and high cost. Therefore, novel techniques for in vitro creation of human 
mAbs may have therapeutic value. A new method to create human monoclonal 
antibodies in vitro involves immortalizing memory B cells with EBV. 
Epstein-Barr virus is a common herpesvirus that is known to efficiently immortalize 
B cells in vitro maintaining them indefinitely in a lymphoblastoid state called an LCL. 
EBV causes na'ive B cells to blast, and LCLs are dependent upon the expression of 8 viral 
genes; EBNAs 1-6 and LMP 1 and 2, However, in vivo, it is known that EBV persists 
mainly in the memory B cell compartment, expressing only EBNA 1, where it can hide 
from the immune system. It is also known that EBV preferentially infects naIve B cells, 
and the current theory on infection is that it exploits the antigen activated B cell 
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differentiation pathway to achieve access to the memory B cell compartment. Antigen 
activated B cell differentiation is thought to be dependent upon T cell help, but has been 
proposed that EBV encoded genes, LMPI and LMP2, may supply signals that force 
differentiation. EBN A2 causes the infected B cell to blast, mimicking the first step of 
antigen activated differentiation. Therefore, it may be feasible that an exogenous supply 
of T cell derived cytokines and EBV encoded genes may force B cell differentiation in 
vitro. 
Since little is known about EBV+ B cell differentiation, it may be advantageous to 
create an in vitro model to investigate this, while simultaneously working to create a 
novel method for the production of human monoclonal antibodies. A good in vitro model 
of EBY+ B cell differentiation might be a valuable tool for the study of Epstein-Barr 
virus, B cell differentiation, EBV related cancer development and, also, antibody 
production. With good primary EBV infection a large portion of the naIve B cell 
repertoire could be immortalized. The addition of T cell derived cytokines and signaling 
factors as well as BCR cross-linkage with anti-IgM (Fab'h to mimic antigen; could force 
in vitro differentiation of EBY+ B cells. With efficient differentiation and class-
switching, antibodies specific to many antigens could be created through non-specific B 
cell differentiation. Should this technology prove feasible, it could circumvent many of 
the current constraints on monoclonal antibody creation. Therefore, novel techniques for 
creating human monoclonal antibodies using EBV may be of therapeutic value. 
Hypothesis: Epstein-Barr virus infection will transform naIve B cells isolated from 
healthy volunteers, and force the differentiation of B cells in vitro through the addition of 
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exogenous T cell derived growth factors along with other signaling agents. 
Differentiated B cells that have undergone isotype class switching and secrete IgG 
antibodies will be assayed for cross-reactivity with a selected antigen of interest, avian 
influenza protein H5 hemagglutinin (HA). 
Specific Aims 
Specific Aim 1. Generation of tonsil and peripheral blood derived B cell repertoires using 
Epstein-Barr virus and cytokines and signaling agents. This aim requiring two steps: 
1. The optimization of EBV infection. Infection efficiency of Epstein-Barr virus 
on B cells will be optimized through analyzing the effects of TLR ligand addition, 
concentration and spinfection of EBV B95-8 and EBafV -GFP viral strains. 
2. The induction of B cell differentiation and immunoglobulin isotype class 
switching in EBV immortalized B cells. Exogenous T cell derived growth and 
stimulation factors as well as B cell receptor cross linkage to mimic antigen will 
be used to induce differentiation. 
Specific Aim 2. The identification and isolation of in vitro differentiated B cell clones 
producing human monoclonal antibodies (IgG) specific for avian influenza protein 
H5HA. 
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Chapter 3: Materials and Methods 
Generation of tonsil and peripheral blood derived B cell repertoires. 
Isolation and culture of tonsil B cells. To prepare B cells from tonsils, tonsil 
tissue was placed inside a sterile Petri dish (VWR International, cat.# 25384-088) 
containing 20-30 ml Dulbecco's phosphate buffered saline (DPBS, without CaCh or 
MgCh , Gibco / Invitrogen, Grand Island, NY cat.#14190144) supplemented with Ix 
Antibiotic-Antimycotic (Gibco / Invitrogen cat.#15240-062). The tissue was chopped and 
minced with scalpels to approximately 1 mm3 pieces. Additional lymphocytes were 
released by gentle grinding of tonsil pieces between the frosted glass surfaces of two 
sterile microscope slides (VWR cat.#12-550-34), and single cell preparation was made by 
straining through 70 11m nylon strainer (BD Falcon, cat.# 352350, BD Biosciences, Two 
Oak Park, Bedford, MA). This suspension was layered onto a Ficoll (Amersham 
Biosciences cat.# 17 -1440-03, Uppsala, Sweden) cushion (35 ml sample over 15 ml 
Ficoll) and resolved at 1500G for 20 min. The boundary layer containing mononuclear 
cells was extracted, washed 2x with DPBS (1300G for 7 min), counted, and re-suspended 
in DPBS.at 108 cells / ml. A highly enriched (>950/0) B-cell population was obtained with 
the use of StemSep Negative Selection Human B-cell Enrichment Kit antibody cocktail 
(cat.#14064A) and magnetic beads (cat.#19150) from StemCell Technologies Inc., 
Vancouver, Canada, according to manufacturer's instructions, with the following 
modifications for use on a "The Big Easy" EasySep magnet (StemCell Tech. cat.#18001). 
All steps were performed in a laminar flow biohazard hood at ambient temperature. The 
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cell suspension was placed in a sterile round bottom 14 ml polypropylene tube (VWR cat 
# 60818-689), mixed with an equal volume of the StemSep Negative Selection Human B-
cell Enrichment Kit antibody cocktail, and incubated for 10 minutes. Then, a volume of 
magnetic bead suspension equal to the antibody cocktail volume was added, followed by 
10 minute incubation. The volume inside the tube was brought to 10 ml with DPBS and 
the tube (minus the cap) was placed inside the magnet for 10 minutes, at which time the 
contents of the tube (still inside the magnet) were gently decanted in a single pour into a 
second sterile 14 ml tube. The original tube with non-B cells adhering to its walls was 
removed from the magnet, and the second tube was inserted for 10 minute clean-up 
incubation. The enriched B-cell suspension obtained after the first and second negative 
selection steps was poured into a 15 ml Falcon tube, counted, washed with DPBS (1300G 
for 7 min) and resuspended in an appropriate volume of complete RPMI media for in 
vitro culture (generally 105 to 106 cells/ml in a 37°C, 5 % CO2 tissue culture incubator. 
Complete RPMI media contains RPMI 1640 (Gibco / Invitrogen cat.#11875-093) -
supplemented with 100/0 fetal bovine serum (FBS, HyClone cat.# SH30088.03, 
lot.#AQC23460, Logan, Utah) -and 100 U/ml Penicillin / 1 00 ~g/ml Streptomycin 
(cat.#15 140-122), 2 mM L-Glutamine (cat.# 25030-081),1 mM Sodium Pyruvate (cat.# 
11360-070), 10 mM HEPES (cat.# 15630-080), 0.1 % 2-mercaptoethanol (cat.# 
21985.023), and 0.1 % Falk's Cloning Cocktail, which consists of 50mM a-thioglycerol 
(Sigma, cat.#M6145), 20~M bathocuprionedisulfonic acid (Sigma, cat.#B 1125), 100mM 
Na pyruvate (cat.# 11360-070), 1M HEPES pH 7.4 (cat.# 15630-080). L-glutamine, 
Sodium Pyruvate, Penicillin/Streptomycin and HEPES were obtained from Gibco / 
Invitrogen. 
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Isolation and culture of peripheral blood B cells. To prepare B cells from 
peripheral blood, venous blood (up to 180 ml) was drawn into 60 ml syringes containing 
1 -5 ml citric acid -or heparin sulfate, which prevent coagulation, diluted with equal 
volume of DPBS, layered onto a Ficoll cushion (35 ml of diluted sample over 15 ml 
Ficoll) and resolved at 2000 rpm for 20 min. Serum (from upper layer) was collected and 
stored in aliquots. The boundary layer containing mononuclear cells was extracted, 
washed 2x with DPBS (1300G for 7 min), counted, and re-suspended in DPBS at 108 
cells / ml. highly pure populations of B-cells are obtained with the use of StemSep 
Negative Human B-cell Enrichment Kit (StemCell Technologies Inc.) as described above 
for isolation of peripheral blood B-cells. Isolated B-cells were washed (1700 rpm for 7 
min) and re-suspended at 105 - 106 cells per ml of complete RPMI media (described 
above), and cultured in a 37°C, 5 % CO2 tissue culture incubator. 
EBV stock preparation. To prepare infectious Epstein-Barr virus (EBV) stocks, 
B95-8 cells (obtained from David A. Thorley-Lawson), a marmoset lymphoblastoid cell 
line (LCL) chronically infected with B95-8 strain EBV [38] or EBfa V -GFP 
cells(described below), were cultured in complete RPMI media (described above) at a 
cell density of approximately 105 cells / ml, in a 37°C, 5 % CO2 tissue culture incubator. 
EBfa V -GFP cells (a gift from Richard Longnecker) were derived from B95-8 cells, 
where the EBV genome was modified by homologous recombination, deleting the 
LMP2a gene and replacing it with enhanced green fluorescence protein (EGFP) (under 
control of the CMV immediate/early promoter) as well as neomycin (neoR) resistance 
gene [39]. These cells contain a mixture of EBfaV-GFP (LMP2-EGFP+) genomes and 
wild-type B95-8 genomes. 
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Approximately 140 ml of cell culture (containing either B95-8 EBV or 
recombinant EBfa V -GFP) was induced to enter lytic virus production phase by treatnlent 
with phorbol myristate acetate (10 ng/ml, Calbiochem, cat. #524400). After a four hour 
incubation with PMA, the PMA was removed from the culture supernatant and replaced 
with complete RPMImedia. The cells were cultured for 3 to 4 days until highly confluent, 
at which point cells were removed by centrifugation (1300G for 7 min), and culture 
supernatant was filtered through 150 ml Nalgene 0.45 ~m vacuum filter (Corning cat 
#430320). Filtered supernatant was either flash-frozen in liquid nitrogen in 1.4 ml 
aliquots for storage at -80°C in 1.5 ml Eppendorf tubes, or concentrated by ultrafiltration 
as described below. 
EBV concentration. Viral concentration was performed by loading the filtered 
supernatant into two Centricon Plus-70 ] units (Millipore, Billerica, MA) and 
concentrated according to manufacturer's instructions. The filter units were centrifuged 
(2000G) for between 15 and 45 minutes (monitored each 15 minutes), until the minimal 
retentate volume (approximately 0.5 ml per filtration unit) was achieved. The filtrate was 
discarded, and virus-containing concentrates were re-suspended with complete RPMI up 
to 14 ml (or 1/10 of the original culture supernatant volume). One ml aliquots were 
transferred into cryovials, flash-frozen in liquid nitrogen, and transferred to -80°C freezer 
for storage. 
B cell infection by inoculation. B cells were resuspended at 106 to107 cells/ml in 
complete RPMI media, and were mixed with an equal volume of filtered EBV 
supernatant, then placed in a T -25 flask and incubated for 4 hours in a tissue culture 
incubator at 37°C and 5% CO2 . The culture volume was then adjusted by the addition of 
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complete RPMI media, such that infected cells were resuspended for cell culture at the 
desired concentration (generally 105 to 106 cells per ml), dispensed into multi-well plates 
and transferred to a tissue culture incubator at 37°C and 5% CO2 • 
B cell infection by spinfection with concentrated EBV stocks. B cells were 
resuspended at 105 cells/ml in complete RPMI media, and were mixed with an equal 
volume of concentrated EBV and placed in a well of a 6 well tissue culture plate (Greiner 
bio-one, cat #65760). The plate was then centrifuged at 900G for 1 hour at ambient 
temperature, at which time infected cells were re-suspended in complete RPMI media at a 
desired concentration (generally 106 to 107 cells per ml), dispensed into multi-well plates 
and transferred to a tissue culture incubator at 37°C and 5% CO2 . 
Infection in the presence of TLR ligands. B cells were infected with B95-S 
strain EBV as described above, with the addition of Toll-Like Receptor (TLR) ligands at 
the time of the infection. The ligands were added at the following final concentrations: 
Pam3CSK4 (0.5 J-lg/ml), zymosan (Zymoson)- (1 J-lg/ml), polyinosine, polycitadylic acid 
poly I:C (25 J-lg/ml), lipopolysaccharide (LPS) (5 J-lg/ml), Imiquimod (1 J-lg/ml), 
unmethylated CpG DNA (1 J-lg/ml). All TLR ligands (from In Vivogen Inc) were 
generously donated by Dr. Mohamed Salem (MUSC). 
Evaluation of B cell immortalization efficiency by lymphoblastoid cell 
outgrowth. At 12 hours post-infection, B cells were counted and dispensed into wells of 
96-well round bottom plates (Greiner cat#650 ISO) as a 2 fold dilution series, with each 
consecutive row of wells containing half the number of cells found in the previous row. 
The initial rows contained 50,000 cells per well, and final rows in the dilution series 
contained 24 cells per well. Cells were incubated for 9 days in a tissue culture incubator 
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at 37°C and 5% CO2, at which point lymphoblastoid cell outgrowth was visible by 
microscopy. Immortalization efficiency was estimated based upon the assumption that 
lymphoblastoid cell proliferation resulted from EBV immortalization of at least one B 
cell in the well. Thus, the efficiency was calculated from rows containing wells with the 
lowest number of cells per well in which lymphoblastoid cell proliferation was 
consistently observed by microscopy, and expressed as 1 immortalization event per 
number of cells originally dispensed into the well. 
Evaluation of EBV .. GFP infection efficiency of 293 cells. Because recombinant 
EBV -GFP virus contains the EGFP gene encoding enhanced green fluorescence protein 
in place of the latent membrane protein-2 (LMP2) gene, infection with the virus can be 
measured by fluorescence microscopy or by flow cytometry as early as 24 hours post-
infection. 293 cells were infected by inoculation or by spinfection as follows. Cells were 
trypsinized, washed and resuspended in complete DMEM media, containing DMEM 
(Mediatech cat.#10-013-CM), 10% Cosmic Calf serum (CCS, HyClone cat.#HS0087.03, 
10t.#APE21241), Penicillin 100 Vlml, Streptomycin 1 00 ~g/ml (Gibco/Invitrogen, 
cat.#15140-122)), at Ix106 cells I 1 ml per well into 6-well plates. 1 mlofEBfaV-GFP 
virus stock, concentrated or un-concentrated, was added to the cells. Plates were either 
incubated overnight for inoculation or centrifuged for 1 hour at 900G for spinfection. 
Infection efficiency was determined 48 hours post-infection by visual inspection using 
fluorescence microscopy. 
Evaluation of EBfa V .. GFP infection efficiency of B cells. To quantitatively 
evaluate B cell infection efficiency, tonsil B cells were dispensed into wells of a 96-well 
plate at 2x 105 cells I 100 J.lI per well. TLR ligands were added to some of the wells at the 
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concentrations previously described above, and cells were incubated for 4 hours at 37°C, 
5% CO2• Concentrated EBfa V -GFP virus stock (100 J.lI / well) was then added to all 
wells and the cells were infected by spinfection as previously described. Infection 
efficiency was analyzed by flow cytometry for EGFP+ cells 24 hours later. 
Flow Cytometry analysis was performed using a Becton Dickinson FACSCalibur 
instrument at the MUSC Flow Cytometry Facility, according to established methods. 
Antibodies are listed in Table 2. 
Induction of B cell differentiation. To determine their effect on B cell 
differentiation during the immortalization process, cytokines and other signaling agents 
were added to EBV infected B cells either immediately after infection, or 16 to 20 hours 
after infection, and twice more at weekly intervals. All agents were diluted in complete 
RPM I media and added to cells at the following final concentrations: recombinant human 
interleukins (IL) IL-4, 0.2 ng/ml; IL-5, 0.2 ng/ml; IL-6, 0.1 ng/ml; IL-9, 0.2 ng/ml; IL-I0, 
2.4 ng/ml; IL-13, 1 ng/ml; recombinant human interferon-a (IFN-a2a), 2,000 IU/ml; 
recombinant human BAFF, 1 ng/ml; recombinant human soluble CD40L, 5 ng/ml; goat 
anti-human IgM (Fab'h, 1.4 ~g/mI. IL-4 (cat. #200-04), IL-5 (cat. #200-05), IL-6 (cat. 
#200-06), IL-9 (cat. #200-09), IL-IO (cat. #200-10), IL-13 (cat. #200-13), CD40L (cat. 
#310-02) and BAFF (cat. #310-13) were obtained from PeproTech (Rocky Hill, NJ). 
IFN-a2a (RoferonR -A) was from Roche Pharmaceuticals, and goat anti-human IgM 
(Fab')2 (cat. #109-006-129) was from Jackson Immune Research Laboratories Inc. 
Creation of immortalized B cell repertoires used in U5 hemagglutinin 
binding studies. Tonsil or peripheral blood B cells were infected by spinfection with 
concentrated B95-8 virus as described above. Immediately following spinfection, cells 
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were resuspended in complete RPM1 media to which 1L-4 (0.2 ng/ml), 1L-6 (0.1 ng/ml), 
BAFF (10 ng/ml), and goat anti-human 19M (Fab'h (1.62 Ilg/ml) (for three samples) or 
CD40L (ng/mL),BAFF (10 ng/ml), and goat anti-human 19M (Fab')2 (1.62 Ilg/ml) (for 
five samples) were added. 
Measurement of human immunoglobulin IgM and IgG production by 
ELISA. Culture supernatants (1 ml from each well of 24 well plates) were collected at 
various time points beginning 1 week after infection and stored frozen at _20DC until 
assay. Thawed supernatants,IOll1 per sample, or lOlll of standards consisting of purified 
human 19G (Sigma-Aldrich cat. #12511) or 19M (cat. #18260), were mixed with 90111 of 
binding buffer consisting of 100 mM Na2HP04, pH 9. Samples were then bound directly 
to quadruplicate wells of Nunc 96-well EasyWash plates (Costar cat. #3369). All 
samples were added to duplicate plates, one for detection of IgG, the other for detection 
of IgM. Plates were incubated at room temperature for 1 hour, washed 4 times with wash 
buffer consisting of PBST (80.0g N aCI, 11.6g N a2HP04, 2.0g KCI, 5ml Tween-20, pH 
7.0 in lOL), and blocked with 2% BSA in wash buffer for 1 hour. Plate bound IgG and 
IgM were detected using alkaline phosphatase (AP) coupled goat anti-human 19G or IgM 
(Southern Biotech cat #2040-04 or 2020-04 respectively), lOOll1 per well diluted 1: 1,000 
was added for 1 hour. After washing, AP conversion of colorimetric substrate p-
nitrophenyl phosphate disodium salt (PNPP, Peirce cat #37620) was detected by 
measuring absorbance at OD405 using a Multiskan Spectrum plate reader 
(ThermoLabsystems). Levels of human immunoglobulin in culture supernatant samples 
were calculated following standard curve calibration of purified human IgG and IgM 
standards using MultiSkan software. 
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Sample collection for HA ELISA analysis. Culture supernatants were collected 
once a week from tonsil and peripheral blood immortalized B cell cultures (150~1 from 
each well, replaced with fresh RPMI plus CD40L, BAFF and anti-human IgM). After 
weeks 1 and 2, the supernatants were pooled by combining 25~1 of sample from each 
well on a plate. For week 3, pooled supernatants were generated from individual rows on 
each plate by combining 50~1 from each well in a specified row (A, B, C, etc). 
Supernatant from the entire well was used for analysis when testing individual or pooled 
dual wells. Once an individual well secreting anti-H5 HA IgG had been identified, cells 
from that well were counted, and subcloned into at least four 96-well plates each 
containing 1000, 100, 10 or 1 cell / well. After 2 weeks, sample collection and analysis 
of supernatants from plates, then rows, then wells were repeated. The goal of the 
subcloning strategy was to obtain H5 HA-reactive IgG from the wells initially plated with 
no more than 1 cell per well. 
H5 HA ELISA. Purified recombinant H5 hemagglutinin (HA) from H5N 1 avian 
influenza strain A / Vietnam / 1203 / 2004 (Protein Sciences Corp) was diluted to 2 
~g/ml in a high pH 100 mM sodium phosphate binding buffer (pH 9.0), dispensed at 50 
~l per well into 96-well Eas-yWash plates (Costar cat. #3369), and allowed to bind 
overnight. To help control for non-specific plate binding in each sample, an equal number 
of wells received binding buffer only. Plates were then washed, and blocked with a 
neutral pH 100 mM sodium phosphate buffer (pH 7.2) containing 2% BSA. Culture 
supernatant from samples or controls 1 00~1 per well was added in triplicate. Controls 
included serum from healthy human volunteers, diluted 1 :500 with complete RPMI 
media; purified human IgG (Sigma) and RituxanR (a humanized anti-CD20 IgG 1 
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monoclonal antibody, Genentech, San Francisco, CA 94080, cat.# 50242-051-21, lot# 
M70267) diluted to 5 ~g/ml in complete RPMI media. Subsequently the plate was 
washed extensively. Next, alkaline phosphatase-coupled goat anti-human IgG diluted 
1: 1,000 (Southern Biotech cat #2040-04) was added 1 00~1 per well, and incubated for 1 
hour at ambient temperature, followed by detection with AP conversion of colorimetric 
substrate consisting of p-nitrophenyl phosphate disodium salt (PNPP, Peirce cat #37620). 
Absorbance was measured at 405 nm. Results were expressed as average 00405 values 
± standard deviations (n=3) Background values resulting from non-specific sample 
binding to uncoated wells (binding buffer only) was subtracted from the values obtained 
from binding to H5 HA coated wells. 
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Chapter 4: Results 
Toll-Like Receptor (TLR) ligands and EBV concentration did not significantly 
improve EBV infectivity. Traggiai et al. (2004) [82] reported that addition of at least 
one TLR ligand (CpG) to cultured memory B cells could enhance EBV infection 
efficiency. Since naIve B cells express several TLR [88] it was reasonable to assess the 
effect of several TLR ligands on EBV infection of naIve B cells. Primary B cells were 
incubated overnight with either Pam3 (Pam3Cys-Ser-(Lys)4) (O.5ug/mL), Zymosan 
(1 ug/mL) , Poly I:C (polyinosinic-polycytidylic acid) (25ug/mL), LPS 
(lipopolysaccharide) (5ug/mL), Imiquimod (1 ug/mL) , CpG (1 Oug/mL), or in unaltered 
media. These are synthetic proteins that mimic antigens and each of these activates 
different TLR and downstream signaling pathways in cells Pam3 (lipopeptides) [89] 
binds TLR 2/1, Zymosan (boiled, trypsin-treated cell wall preparation of Saccharomyces 
cerevisiae) binds TLR 2/6, Poly I:C (viral double stranded DNA mimic) binds TLR 3, 
LPS (a microbial cell wall component) binds TLR 4 [89], Imiquimod (small-molecule 
compound in the imidazoquinoline family that displays both antiviral and antitumor 
effects) binds TLR 7, and CpG (hypomethylated DNA) binds TLR 9 [89]. We chose 
these TLR ligands because they activate a wide range of TLR and give a good range of 
acti vities. Then B cells were infected with unconcentrated EBV (B95-8) from preparation 
1 or 2 (prep 1, prep 2). In figure 4.1A, Imiquimod, Pam3 and CpG addition, did improve 
infection efficiency to nearly 1.5% in some cases. But, the overall infectivity was 
unacceptably low compared to control B cells not treated with TLR ligands (Figure 
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4.1A). Viral preparation did have an effect on viral infectivity; this could be a result of 
induction of stock cells (Figure 4.1A). 
Since TLR ligands did not increase infection, viral concentration was pursued 
because higher viral titer was achieved with retrovirus infection [40]. Viral concentration 
can be achieved through several techniques. For our studies, we used ultra filtration 
centrifugation to concentrate EBV. Concentrated or unconcentrated EBV was applied to 
primary B cells, and infectivity was determined through blast formation. Our findings 
indicate that concentration of EBV improved infection efficiency to nearly 5%, as 
compared to un-concentrated virus from the same preparation which reached only 1 % 
infectivity (Figure 4.1B). Although TLR ligands had little effect on infectivity, viral stock 
preparation varied in infectivity (Figure 4.1A and B). Viral concentration did increase 
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Figure 4.1. Effect of TLR ligands and viral stock concentration on EBV infection 
efficiency. Primary tonsil B cells (106 cells/mllwell) were seeded in 24-well plate and 
infected with 1 ml of concentrated through ultra filtration centrifugation using Centricon 
Plus-70 or un-concentrated B95-8 viral stocks from several different preparations, with 
the addition of various TLR ligands as indicated; Pam3 (lipopeptides) [89] binds TLR 
2/1, Zymosan (boiled, trypsin-treated cell wall preparation of Saccharomyces cerevisiae) 
binds TLR 2/6, Poly I:C (viral double stranded DNA mimic) binds TLR 3, LPS (a 
microbial cell wall component) binds TLR 4 [89], Imiquimod (small-molecule compound 
in the imidazoquinoline family that displays both antiviral and antitumor effects) binds 
TLR 7, and CpG (hypomethylated DNA) binds TLR 9 [89]. (see Materials and Methods). 
After a 4 hr incubation, cells were dispensed into a 96-well plate using a 2-fold serial 
dilutions, starting at 5x 104 cells/well and ending with 24 cells/well. LCLs were scored 
visually by phase contrast microscopy 9 days post-infection. Percent (%) immortalization 
efficiency was calculated as described in Materials and Methods. Means ± SD are shown 
(n ~ 3). A. Effect of TLR ligands and viral preparation B. Effect of virus stock 
concentration. 
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The combination of viral concentration and "spinfection" increased in EBV 
infectivity. "Spinfection" or "spinoculation" has been reported to enhance the infectivity 
of other enveloped viruses, such as HIV [91, 92]. This technique involves combining 
cells with viral stock, then centrifuging this combination at low speeds for one hour. To 
evaluate concentration and "spinfection" techniques, Q293A cells, an adherent cell line, 
were infected with a recombinant EBfa V -GFP virus; one of the latent EBV genes, 
LMP2a, was replaced with the enhanced green fluorescent protein EGFP gene in this 
virus [39]. Q293A cells were inoculated for 24 hours with concentrated preparations of 
EBfa V -GFP or "spinfected" (900xG) with concentrated virus for 1 hour. In Figure 4.2A a 
good portion of cells were infected with a 10-fold concentration of EBfa V -GFP. In 
Figure 4.2B, Q293A cells were treated with concentrated virus and "spinfected", the 
combination increased infection efficiency over concentrated virus infection (Figure 4.2). 
While "spinfection" and EBV concentration increased infection efficiency of an 
established cell line, this technique still needed to be evaluated and infection efficiency 
needed to be quantified on primary B cells, our primary target. Tonsil B cells were 
"spinfected" with concentrated non-fluorescent B95-8 EBV or EBfaV-GFP and analyzed 
by flow cytometry for GFP expression levels 24 hours post infection. Visual inspection 
of the infection efficiency revealed that the combination of concentration and 
"spinfection" was effective (Figure 4.3A). The infection efficiency was quantified by 
flow cytometry 24 hours after infection, and compared with non-fluorescent B95-8 
infected cells. The combination of "spinfection" and concentration significantly 
increased EBV infection of primary B cells. This method doubled the fluorescence of 
virally infected B of which 45% of the cells were fluorescing above non-fluorescent 
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infected cells, with an MFI of 61.9 (Figure 4.3B). An entire peak shift indicates that 
nearly 100% of B cells are transuded using this method. This infection efficiency was a 
great improvement over inoculation with un-concentrated virus (1-2%) and would be 
sufficient for immortalizing a large portion of the B cell repertoire. 
Our results for the optimization of EBV infection of B cells indicated that TLR 
ligand stimulation and viral concentration did not increase infection efficiency adequately 
for our needs. However, the combination of viral concentration and "spinfection" 
dramatically increased infection of primary B cells. 
A. B. 
1 O-fold concentration concentration + spinfection 
Figure 4.2. Effect of EBV concentration and spinfection on infection efficiency. 
Q293A cells were trypsinized, counted and seeded at lxl06 cells/lml/well into 6-well 
plates , and 1 ml of EBfa V -GFP concentrated stock, was added to the cells. Plates were A. 
incubated overnight with concentrated EBfa V -GFP or B. cells were treated with 
concentrated EBfa V -GFP centrifuged for 1 hour at 900G for spinfection. EGFP 
fluorescence was detected with inverted microscope (lOX objective) 48 hr post-infection. 
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Figure 4.3. Efficient infection of primary tonsil B cells with EBfa V ·GFP. B cells 
(2xl05 cells/O.lml/well) were seeded into a well of 96-well plate, mixed with 0.1 ml of 
10-fold concentrated EBfa V -GFP and "spinfected" or "spinoculated" at 900G for 1 hour. 
Sin1ilar number of cells was infected with B9S-8 as a negative fluorescence control. 
Infection was evaluated 24 hours later, either as A. visual evaluation of infection 
efficiency with fluorescent microscope; or B. a flow cytometry analysis of infection. Gate 
indi<;ates that 4S% of cells fluoresce above background with a mean fluorescence 
intensity (MFI) shift from IS.1 +/- 6.2 for B9S-8 infected cells in grey to 61.9 +/- 22.6 for 
EBfa V -GFP infected cells in green peak. The shift of the entire peak indicates nearly 
1000/0 infection efficiency. 
39 
T cell derived cytokines had varying effects on IgM and IgG secretion from 
different samples. NaIve B cells are activated through interactions between the B cell 
receptor (BCR) and specific antigen, which is helped by co-stimulatory signals from T 
cells. B cell differentiation in vivo is dependent upon T cell help. Therefore, our lab 
postulated that if we could supply both T cell derived growth and differentiation factors, 
while cross-linking the BCR to mimic antigen, we could force EBV immortalized LCLs 
to differentiate in vitro. 
To test this postulate, we examined the effect that different cytokine combinations 
had on differentiation specifically, as determined by IgG secretion. To examine the 
specific effects that these cytokine combinations had on IgM and IgG secretion, primary 
tonsil B cells were infected with B95-8 EBV, treated with cytokines or other agents listed 
in Table 4.1 or the combinations of these outlined in Figure 4.4 and culture supernatant 
was analyzed for IgM or IgG with ELISA. Figure 4.4 shows the secretion pattern of IgM 
and IgG in three different samples, one week after infection and treatment. IgM was 
primarily secreted in higher levels than IgG by all of the samples in most cytokine 
treatments (Figure 4.4). Specifically, BAFF and CD40L and anti-IgM (Fab'h increased 
IgM secretion over untreated cells (Figure 4.4). Alternatively, B cells treated with 
cytokine combinations containing the anti-viral cytokine, IFN-a decreased total 
immunoglobulin secretion after one week, when compared to untreated controls. Since a 
similar pattern of expression was obtained from three different samples, cytokine 
combinations had similar effects over several samples. Also, since the majority of 
immunoglobulin secretion was IgM, a large portion of the tonsil B cells were nai·ve. 
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Ta~le 4.1: Cytokines and other stimulating factors used to induce 
class switching and differentiation of B cells 
Name Function Working 
Concentration 
Anti-IgM Goat anti-human IgM (Fab')2; crosslinks IgM, mimics 1.4 f.1g/ml 
(Fab')2 specific antigen binding [41]. 
IL-4 Cytokine produced by activated T cells and other 0.2 ng/ml 
immune cells. Participates in several B-cell activation 
processes: increased viability and proliferation rate, 
enhanced secretion and surface expression 
immunoglobulin [41]. 
IL-5 Cytokine secreted by T cells; acts as a growth and 0.2 ng/ml 
differentiation factor for both B cells and eosinophils; 
promotes production of immunoglobulin [42]. 
IL-6 Cytokine plays role in the final differentiation of B-cells 0.1 ng/ml 
into Ig-secreting plasma cells [43]. 
IL-9 Cytokine secreted by Th2 cells; stimulates cell 0.2 ng/ml 
proliferation and growth [44]. 
IL-I0 Cytokine produced primarily by monocytes and 0.24 ng/ml 
'. lymphocytes; enhances B cell survival, proliferation, 
and antibody production[97]. 
IL-13 Cytokine produced by activated T cells; involved in B- 1 ng/ml 
cell maturation, differentiation and Hodgkin's 
... development [45] . 
Interferon Cytokine produced by stimulated T lymphocytes and 2000lU/mi 
a (IFNa many other cell types; enhances MHC I and II 
2a) expression, activates a subset of antiviral genes [46]. 
BAFF The B lymphocyte activating factor; expressed by 1 ng/ml 
monocytes, macrophages and DCs, plays a central role 
in B lymphocyte development and activation [47]. 
CD40L A ligand for CD40; CD40 signaling induces B cell 5 ng/ml 
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Figure 4.4. IgG and IgM secretion profiles of B-cells from three tonsil samples 
treated for 1 week with different signaling agents. Tonsil B cells from 3 separate 
samples were prepared, inoculated with B95-8, seeded into 24-well plates, and treated 
with indicated signaling agents and cytokine combinations as described in Materials and 
Methods. Culture supernatants were collected. one week post-infection, and analyzed by 
ELISA for IgG and IgM levels as described in Materials and Methods. Means ± SD of 
samples and controls (n=4) are shown. 
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Cytokines and signaling agents induce isotype class switching after several weeks in 
culture. Cytokines and other signaling factors are necessary for B differentiation in vivo, 
therefore we studied the effects of these signaling factors on EBV immortalized LCL. 
Tonsil B cells were treated with cytokines and signaling agents for three weeks, and 
supernatant was analyzed by ELISA after each week for up to 10 weeks. The tonsil B 
cells from two samples received on different dates (Figure 4.5) were treated with the 
same cytokine combinations for three weeks. These samples secreted primarily IgM after 
one week (Figure 4.4). However, expression pattern of IgM and IgG changed with time 
in vitro. After 8 to 10 weeks in culture the immunoglobulin expression pattern was 
clearly different. Continued cytokine treatments with CD40L alone, or anti-IgM (Fab')2 
in combination with IL-6, resulted in high levels of IgG secretion (Figure 4.5 A and B). 
This increase in IgG was accompanied with a drop in IgM secretion. On the other hand, B 
cells treated with anti-IgM (Fab'h and IL-4 secreted more IgM after several weeks, 
however, it was only observed in one of the samples (Figure 4.5 A). The B cells in our 
studies continued to secrete immunoglobulin at high levels for many weeks. These results 
suggested that the LCLs had undergone immunoglobulin isotype class switching from 
IgM to IgG through cytokine treatment. 
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Figure 4.5. IgM and IgG expression profile after 8 weeks in culture of 2 
representative samples following 3 weekly treatments with cytokines and signaling 
agents. B cells from two tonsil samples were isolated, inoculated with B95-8 EBV, 
seeded into 24-well plates, and treated with the indicated combinations of cytokines and 
signaling agents as described in Materials and Methods. Cells were treated once a week 
for the first 3 weeks, and the culture supernatants were collected weekly. Culture 
supernatants collected on week 8 post-infection were analyzed by ELISA for IgG and 
IgM levels as described in Materials and Methods. Two samples are shown here (A and 
B), created from tonsils. Means ± SD of samples and controls (n=4) are shown. Signaling 
agent combinations that contain anti-IgM (Fab')2 were highlighted in yellow and 
combinations that promoted immunoglobulin isotype class switching are bracketed in 
black. 
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Cytokine treatments induced differentiation of primary B cells to early plasma like 
B cells. Figure 4.5 demonstrated that, in general, cells treated with anti-IgM (Fab'h and 
IL-6 increased IgG secretion and cells treated with anti-IgM (Fab'h and IL-4 increased 
IgM secretion. Immortalized cells secreted high amounts of immunoglobulin for upwards 
of 20 weeks (data not shown). These observations, when taken together, indicated that B 
cell differentiation had occurred. In order to investigate whether naIve B cells had 
become plasma cells in vitro, primary B cells and IgM and IgG secreting B LCLs were 
stained for common B cell markers (Table 4.2). Figure 4.7 shows that uninfected primary 
tonsil B cells were mostly naIve; all were CD 19, CD20 positive and large portions were 
IgG positive. All had low expression of activation markers CD27 and CD30 (Figure 4.6 
A). Conversely, IgM and IgG secreting cells were both similar to early plasma cells; all 
were CD 19 positive and CD20 and IgD low and all had increased expression of the 
activation markers CD30 and CD27 (Figure 4.6 B). IgG and IgM secreting cells differed 
only in the expression of CD38, a terminal differentiation marker, which was up-
regulated on IgG secreting cells (Figure 4.6 B). These results confirmed that the cytokine 
treated cells had undergone differentiation into immunoglobulin secreting plasma cells in 
vitro and isotype class switching had been induced with the addition of anti-IgM (Fab'h 
and IL-6. 
Summary: To date, Epstein-Barr virus infection of primary B cells has been optimized to 
achieve nearly 100% infection efficiency through viral concentration and "spinfection". 
Cytokine combinations with CD40L alone or anti-IgM (Fab'h in combination with IL-6 
or IL-9 and IL-13 increased activation of B cells and induced B cell differentiation to 
yield high amounts of IgG secretion have been identified. The staining pattern of in vitro 
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LCLs as compared to pnmary B cells indicated that cytokine treated LCLs have 
differentiated and resemble early plasma stage cells that secreted IgG antibodies for 
months in culture, an indication of in vitro differentiation. 
80 • Primary "0 Q) t3 60 • Q) IgM high C 40 'c • IgG high ::J 20 
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Figure 4.6. Immortalized B cells cultured with anti-IgM (Fab'h and IL-4 or IL-6 
differentiated to early plasma "like" cells in vitro. Expression of indicated cell surface 
markers (role of which is summarized in Table 4.2) was evaluated by flow cytometry (see 
Materials and Methods) in A. primary tonsil B cells (green) and B. immortalized B cells 
cultured for 19 weeks, with either anti-IgM (Fab')2 and IL-4, which secrete high IgM 
levels (red) or anti-IgM (Fab'h and IL-6, which secrete high IgG levels (blue). 
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Table 4.2. Cell determinants used to characterize B cell 
populations by flow ·cytometry 
Marker Function Expression 
CD19 Assembles with the BCR in order to Pantropic B-cell marker 
decrease the threshold for antigen-specific 
receptor-dependent stimulation 
CD20 B cell surface molecule with a role in the Present on all mature B 
differentiation and development of B cells lymphocytes, except plasma 
into plasma cells cells 
CD27 Member of the NGFITNF receptor Marker for human 
superfamily; present on germinal center B- somatically mutated cells. 
cells. Soluble CD27 is produced by plasma Found on both Band T 
B cells I ymphocytes upon cell 
activation 
CD30 Transmembrane cytokine receptor Upregulated on post-
belonging to the TNF superfamily, has a germinal center cells; 
role in regulating the function, present on Hodgkin's and 
differentiation an/or proliferation of Reed-Sternberg cells and on 
normal lymphoid cells tumor cells of anaplastic 
large cell 
CD38 Functions in cell adhesion, signal Expressed at multiple 
transduction and calcium signaling. stages; first appears on bone 
marrow precursor cells but 
is lost on mature 
lymphocytes; it protects 
germinal center cells from 
apoptosis, but memory cells 
exiting the germinal center 
lack Cd38; present on 
terminally differentiated B 
cells 
IgD Immunoglobulin molecule with unknown Present on mature naIve B 
function lymphocytes 
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Monoclonal antibody production 
HSN! Hemagglutinin (HA) specific antibodies are found in sera of healthy humans. 
The creation of plasma like cells in vitro, suggested that the process might be exploited 
for the creation of human monoclonal antibodies specific for targets of interest, like avian 
influenza. While most people have not been exposed to avian influenza, they have been 
exposed to other closely related flu strains. Therefore it is reasonable to assume that 
healthy individuals may have memory B cells that were stimulated by human influenza 
viruses and which cross-react with the H5 HA protein of avian influenza. To confirm if 
H5 HA cross-reactive IgG antibodies are present in the blood of healthy individuals, 
serum was collected from five healthy volunteers (HS 1-5) and assayed by ELISA for 
antibodies that bind to recombinant commercially obtained H5 HA. To detect these 
antibodies in the serum, an ELISA using recombinant H5 HA was created. H5 HA 
specific binding was calculated by subtracting total binding to H5HA from background 
binding (described in methods). Volunteers 1, 2, 3 and 5 (HS 1, 2, 3, 5) had varying 
amounts of HA-specific IgG in the serum (Figure 4.7) with donors 3 and 5 having the 
highest reactivity. However, Volunteer 4 (HS 4) had lower reactivity than our controls, 
Rituxan (Rituximab) and purified total human IgG (sigma), indicating that this volunteer 
lacked H5 HA cross-reactive IgG antibodies (Figure 4.7). The detection of H5 HA-
specific IgG in the serum of healthy volunteers indicated that our ELISA was capable of 
detecting H5 HA reactive IgG antibodies. Conversely, we could not use the ELISA to 
detect IgM antibody binding because background binding was too high (data not shown). 
The positive results for HA-specific IgG antibodies bolstered the hypothesis that IgG 
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antibodies specific for H5 hemagglutinin of aVIan influenza could be created by 
exploiting the B cell differentiation pathway. 
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Figure 4.7. H5 HA-reactive antibodies are present in human sera from individuals 
never exposed to H5Nl avian influenza. Samples or controls, rituxan and purified 
human IgG, 0.1 ml per well were added in triplicate to ELISA plates previously coated 
with recombinant H5 or to uncoated control wells. Rituxan and purified human IgG were 
diluted to 5 mg/ml while human sera were diluted 1: 1000 in complete RPMI media. 
Plates were washed, blocked and probed with anti-human IgG as described in the 
methods . H5 HA coated plates were prepared by overnight incubation with recombinant 
protein diluted to 2 ~g/ml in binding buffer, 0.1 ml per well. To help control for 
background non-specific binding, each sample was added to an equal number of control 
uncoated wells. Specific IgG binding to H5 HA was calculated by subtracting out the 
values obtained from background binding to the control uncoated wells; mean absorbance 
at OD405 ± SD of samples and control are shown (blue bars). 
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Immortalized B cell repertoires from PBM C secreted IgG antibodies specific for H5 
HA. The ELISA results suggested that B cell clones of a given specificity could be 
isolated from individuals that have not been exposed to H5N 1 avian influenza. To test 
our immortalization and differentiation techniques, PBMC were extracted from Volunteer 
5 (HS5=V5) who demonstrated high levels of H5 HA reactive antibodies in the serum. B 
cells were cultured using two different cytokine/signaling agent combinations: (1) anti-
IgM (Fab'h, IL-4 and IL-6 (PBMC AI), (2) anti-IgM (Fab')2, CD40L and BAFF (PBMC 
A2). 
PBMC AI: B cells were isolated from PBMC of volunteer HS 5 and immortalized with 
.EBV (Table 4.3). Cells were treated with anti-IgM (Fab')2, IL-4 and IL-6 to induce high 
levels of immunoglobulin production, and plated in 3 96 well plates. Supernatant was 
collected and pooled, and after one week there was little or no H5 HA-specific IgG 
binding detected in the supernatant from any of the three plates, compared to human 
serum controls (Figure 4.8). However, after two weeks of cytokine treatment H5 HA-
specific IgG was detected in the supernatant from all three of the plates of B cells (Plate 1, 
Plate 2 and Plate 3) (Figure 4.8). To determine the location of the reactive B cell clones 
rows on reactive plates were pooled and assayed, then wells in reactive rows were pooled 
and assayed. Several rows from each of the three plates contained cross-reactive B cells 
(plate 1, row E; plate 2, rows C, D and E; and plate 3, row D) (Figure 4.9). Figure 4.11 
indicates that the most cross-reactive B cells were located on plate 2, in row D, wells 11 
and 12 (Figure 4.10). With further analysis of the supernatant the reactive B cell clones 
were found to be on plate 2, in row D, well 11 (Figure 4.11); these clones were secreting 
H5 HA-specific IgG at a level similar to our positive serum control (Figure 4.11). This 
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well has since been subcloned, and identification of H5 HA-reactive clonal B cell 
population is being pursued. A summary of the clonal isolation scheme and findings are 






























plate 1 plate 2 plate 3 
V-5 culture supernatants 
from pooled wells 
, I 
.• week 1 
I 
' . week 2 ! 
V-5 purified 
serum human IgG 
Figure 4.8. Immortalized peripheral blood B cells from volunteer V -5 were 
stimulated to produce IgG that binds H5 HA. EBV -immortalized B cells were 
stimulated to produce IgG with anti-human IgM (Fab')2, IL-4, and IL-6 as described in 
methods, and cultured in 3 96-well plates (104 cells per well). After week 1 (blue bars) 
and week 2 (red bars), 150~1 culture supernatants from all wells on each plate were 
collected and pooled, then tested for H5 HA binding as described in the Materials and 
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Figure 4.9. H5 HA specific IgG production in culture supernatant from individual 
rows on plates containing immortalized B cells identified with binding activity, from 
PBMC Al sample. 150111 of culture supernatants from all wells in each row of reactive 
plates 1, 2 and 3 were pooled and assayed for H5 HA binding as described in the 
Materials and Methods. Mean absorbance at OD405 ± SD of samples and controls (n=3) 
are shown. Rows with significant H5 HA binding (Plate 1, row E, Plate 2, rows C, D and 
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Figure 4.10. H5 HA specific IgG production in culture supernatant from paired 
wells of rows on plates identified with binding activity, from PBMC Al sample. 
Week 3 culture supernatant from pairs of adjacent wells in H5 HA reactive rows 
identified in Figure 4.9 were pooled and assayed for H5 HA binding as described in the 
Materials and Methods. Mean absorbance OD405 ± SD of samples and controls (n=3) are 
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Figure 4.11. H5 HA specific IgG production localized to plate 2 well Dll, from 
PBMC Al sample. Culture supernatants from individual wells on plate 2, D 11 and D 12, 
were assayed for H5 HA binding as described in Materials and Methods. Mean 
absorbance OD405 ± SD of samples and controls (n=3) are shown. H5 HA reactivity at a 
level similar to that found in human serum controls was observed in well D 11; cells from 
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Figure 4.12. Subcloning strategy of H5 HA specific B cells found in plate 2 well Dll, 
from PBMC AI. EBV-immortalized B cells from PBMC Al were stimulated to produce 
IgG with IL-4, IL-6, BAFF and anti-human IgM (Fab')2 (see Materials and Methods), 
and cultured in three 96-well plates (104 cells per well). H5 HA binding was determined 
as described in the Materials and Methods. Culture supernatants from all wells on each 
plate were collected (150!!1 per well), and 50~1 per well were pooled and assayed for H5 
HA binding. All plates contained H5 HA-reactive IgG after two weeks and culture 
supernatants from individual rows on these plates were pooled and assayed on week 3. 
Plate 1, row E, Plate 2, rows C, D and E, and Plate 3, row D had significant H5 HA 
binding. Culture supernatants from dual adjacent wells on each reactive row were 
assayed, identifying wells 5 and 6 on Plate 1 and wells 11,12 on Plate 2, row D as 
having, H5 HA binding. On week 5, reactive well D lIon Plate 2 was identified in a 
similar manner, and cells from this well were subcloned by limiting dilution analysis in 
96-well plates containing 1, 10, 100 or 1,000 cells per well. At weekly intervals 
thereafter, culture supernatants from all wells on each plate were pooled and tested by 
ELISA for H5 HA binding. Identification of a potentially clonal population secreting IgG 
reactive with H5 HA was isolated from well Dl1 of the plate containing 1 ceJI per well 
on week 8. The isolation strategy is summarized. Mean absorbance OD405 ± SD of 
samples and controls (n=3) are shown. 
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PBMC A2: B cells were isolated from PBMC of Volunteer HS 5 a second time and 
infected with EBV (Table 4.3). Cells were immediately treated with cytokines anti-IgM 
(Fab' )2, CD40L, and BAFF, which improved levels of IgO antibody production over the 
combination used on PBMC A and B. Supernatant was collected, pooled and assayed for 
H5 HA reactive IgG antibodies in 6., 96 well plates. After 4 weeks, three wells on two 
plates (Plate 4 08, Plate 5 El and Plate 6 C2) contained cross-reactive IgG; the cross-
reactive wells were identified as outlined in figure 4.13. The three reactive wells have 
been subcloned, and an H5 HA-reactive clonal population is being pursued. After 
subcloning the binding of some of the antibodies was lost, this is demonstrated in Figure 
4.13. 
PBMC B: B cells were isolated from peripheral blood of Volunteer 6 and immortalized 
with EBV (Table 4.3). The LCLs were treated with cytokines and signaling agents (anti-
IgM (Fab')2, IL-4 and IL-6) and plated in 3, 96 well plates. After three weeks of 
treatment, no H5 HA -specific IgG antibodies were detected in the supernatant or serum 
of Volunteer 6 (Figure 4.14). Analysis of this sample was discontinued due to a lack of 
H5 HA cross-reactive IgG in the serum and supernatant of the LCLs. 
Summary: Peripheral blood derived B cells from two volunteers were isolated and 
immortalized with EBV. B cells that secreted H5 HA reactive IgG antibodies were 
isolated from one of the volunteers., on two separate occasions (PBMC A 1 and A2), 
which indicates that the results are reproducible. The cytokine and signaling agent 
combinations were changed to improve isotype class switching and obtain more H5 HA 
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reactive IgG secreting B cell clones in our samples. This change yielded more reactive 
clones in PBMC A2 than in PBMC Al. The samples were isolated from the same 
volunteer a little over a month apart. In contrast, B cells isolated from Volunteer 6 did not 
yield any reactive clones and there was also no H5 HA-reactive IgG in the serum of the 
individual. These results are summarized in Table 4.3. 
Immortalized B cell repertoires from tonsils secreted IgG antibodies specific for H5 
HA. While B cells that produced H5 HA-specific IgG were successfully isolated and 
immortalized with EBV from peripheral blood (PBMC), in order to prove that we were 
inducing differentiation of naIve B cells, we needed to obtain a naIve population thus we 
used tonsil B cells from healthy children undergoing tonsillectomy. Cytokine/signaling 
agents treatment was changed from anti-IgM (Fab'h, IL-4 and IL-6 for the first tonsil 
(TNSL A) to anti-IgM (Fab')2, CD40L and BAFF for the rest (TNSL B thru E), because 
the second combination was shown to selectively increase IgG secretion. We repeated the 
experiments performed on the peripheral blood samples on 5 tonsil samples. 
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PBMC A2: Subcloning Scheme 
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Figure 4.13. Sub cloning strategy for isolation of H5 HA specific B cell clones from 
PBMC A2. EBV immortalized B cells from PBMC A2 were stimulated to produce IgG 
by treatment with anti-IgM (Fab'h, CD40L and BAFF, and cultured in six 96-well plates 
(104 cells per well). H5 HA binding was determined as described in materials and 
methods. Culture supernatants from all wells on each plate were collected (150~1 per 
well), and 50~1 per well were pooled and assayed for H5 HA binding. Plate 4, 5 and 6 
were reactive with H5 HA, and culture supernatants from wells in each row on these 
plates were pooled and assayed (week 2). Supernatants in dual adjacent wells from 
reactive rows D and G on Plate 4, row E on Plate 5 and row C on Plate 6 were collected 
and analyzed for H5 HA reactivity (week 3). The reactive wells G8 on Plate 4, El on 
Plate 5 and row C3 on Plate 6 were subcloned by limiting dilution analysis into 96-well 
plates containing 1, 10, 100 or 1,000 cells per well on week 4. Culture supernatants from 
all wells on each plate were pooled and tested by ELISA for H5 HA reactivity, 
identifying potential clonal populations of cells subcloned from Plate 4 and Plate 6 after 
8-9 weeks. Mean absorbance OD405 ± SD of samples and controls (n=3) are shown. 
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Figure 4.14. Lack of H5 HA specific B cells in PBMC B. EBV immortalized B cells 
from PBMC B were stimulated to produce IgG with IL-4, IL-6 and anti-IgM (Fab'h, and 
cultured in three 96-well plates «104 cells per well). H5 HA binding was determined as 
described in materials and methods. Culture supernatants from all wells on each plate 
(150~ 1 per well) were collected, and 50~1 per well were pooled and assayed for H5 HA 
binding. This was repeated for three consecutive weeks without significant detection of 
H5 HA, at which point screening was discontinued. Mean absorbance OD405 ± SD of 
samples and controls (n=3) are shown. 
61 
Sample I #of B #of # # Cytokine IgG specific for I Status 




PBMC 0.2 3 1 3 Anti-IgM (Fab')2' IL- Positive Subcloned one well on plate 2 
Al 4, IL6 
and identified one possible clone, ongoing 












Anti-IgM (Fab')2' Positive Subcloned three wells (E I, G8 and C2) from 
A2 CD40L, BAFF 
plates 1,2 and 3 respectively. Currently screening 
possible clonal populations from two plates, 
0\ I I I I I I ongoing 
N I 
f I I I I Anti-IgM (Fab')2' IL-TNSLA 20 10 2 0 Positive Screening discontinued, sample lost to 
4,IL6 contamination 
TNSLB I 20 I 10 I 0 I 0 I Anti-IgM (Fab')2' Negative Screening discontinued after 4 weeks 
CD40L, BAFF 
J 
TNSLC I 22 I 10 I 0 I 0 I Anti-IgM (Fab')2' Negative I Screening discontinued after 3 weeks 
CD40L, BAFF 
TNSLD I 15 I 10 I 1 I 1 I Anti-IgM (Fab')2' Positive Subcloned one well (G4) from plate 10, screening 
CD40L, BAFF of clonal populations is ongoing 
TNSLE I 4 I 4 I 1 I 1 I Anti-IgM (Fab'h, Positive Subcloned well AIO from plate 3, screening and 
CD40L BAFF subcloning is ongoing 
TNSL A: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, treated 
with (anti-IgM (Fab'h, IL-4 and IL-6) and cultured in 10, 96 well plates as described in 
the methods. After one week, no H5 HA reactive IgG was detected. However, after two 
weeks of cytokine treatments, H5 HA binding activity was detected on two (Plates 6 and 
9) out of ten plates (Figure 4.15). After three weeks, two rows (C and F on Plate 9) were 
identified as having H5 HA reactive IgG, unfortunately, this sample was lost to fungle 
contamination contamination and analysis was discontinued (Figure 4.15). Despite the 
loss, this sample demonstrated that IgG reactivity to our antigen of interest was possible 
from naIve tonsil B cells. 
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Week 1 plates 
Week 2 rows and -
plates 
Week 3 rows and -
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TNSL A: Subcloning Scheme 
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1- 1- 1- 1 
* Contamination 
Figure 4.15. H5 HA specific IgG identified in supernatant from TNSL A. EB V 
imn10rtalized B cells from TNSL A were stin1ulated to produce IgG with IL-4, IL-6 and 
anti- IgM (Fab' h, and cultured in ten 96-well plates « 1 04 cells per well). Culture 
supernatants from all wells on each plate (l50~ I per well) were collected, and 50~1 per 
well were pooled and assayed for H5 HA binding. Week 1 analysis showed no reactivity, 
while reactivity was detected on Plates 6 and 9 on week 2. Culture supernatants fr0l11 all 
wells on individual rows on Plates 6 and 9 were pooled and assayed for H5 HA binding 
as described in materials and methods. Rows C and F on Plate 9 were reactive; however, 
the sample was lost due to fungal contan1ination after week 3, and screening was 
discontinued. Mean absorbance 00405 ± SO of san1ples and controls (n=3) are shown. 
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TNSL B: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, treated 
with anti-IgM (Fab'h, CD40L and BAFF, to increase IgG antibody production and plated 
in 10, 96 well plates. In the first week, H5 HA reactive IgG was detected on Plate 3 
(Figure 4.16). However, after two weeks of analysis row D of Plate 3 was slightly 
reactive, but no reactivity was recovered after four weeks. Therefore, sample analysis 
was discontinued (Figure 4.16). 
TNSL C: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, 
stimulated with anti-IgM (Fab'h, CD40L and BAFF and plated in 10, 96 well plates. 
After the first week, H5 HA reactive IgG was detected on plates 7, 8, 9 and 10 (Figure 
4.17). However, after two weeks no H5 HA cross-reactive IgG antibodies were detected 
on any of the plates and no reactivity was recovered after four weeks. Therefore, sample 
analysis was discontinued (Figure 4.17). 
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Week 1 
Week 2 plates 
and rows 
Week 3 plates 
and wells 
Week 4 plates 
and wells 
TNSL B: Subcloning Scheme 
1 +1 
0+/-
- I - I 1- 1- 1 
Figure 4.16. Lack of HS HA specific IgG in supernatant from TNSL B. EBV 
immortalized B cells from TNSL B were stimulated to produce IgG with CD40L, BAFF 
and anti-IgM (Fab'h, and cultured in ten 96-well plates (2 x 105 cells per well). Culture 
supernatants from all wells on each plate (150I-.d per well) were collected, and 50111 per 
well were pooled and assayed for H5 HA binding. Week 1 analysis showed low level 
reactivity on Plate 3, and culture supernatant from row D on Plate 3 was weakly reactive 
on week 2; however, after weeks 3 and 4, no H5 HA reactivity could be detected on any 
o~ the plates, and screening was thus discontinued. Mean absorbance OD405 ± SD of 
samples and controls (n=3) are shown. 
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Week 1 plates 
Week 2 plates 
and rows 
Week 3 plates 
and wells 
TNSL C: Subcloning Scheme 
+/- +/- +/- +/-
Figure 4.17. Lack of H5 HA specific IgG in culture supernatants derived from 
immortalized from TNSL C B cells. EBV immortalized B cells from TNSL C were 
stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab')2, and cultured in ten 
96-well plates (>2 x 105 cells per well). One week later, culture supernatants from all 
wells on each plate (150lll per well) were collected, and 50111 per well were pooled and 
assayed for H5 HA binding. Significant H5 HA specific binding was not detected on any 
plates. Mean absorbance OD405 ± SD of samples and controls (n=3) are shown. 
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TNSL D: B cells were isolated from tonsil (Table 4.3), immortalized with EBV, 
stimulated with anti-IgM (Fab'h, CD40L and BAFF and plated in 10, 96 well plates. 
After one week, there was no detectable H5 HA reactive IgG in the culture supernatant 
(Figure 4.18). However, after 2 weeks, H5 HA reactive IgG was identified on plates, 1, 8, 
9 and 10 (Figure 4.19). Plate 10 exhibited H5 HA-reactivity as high as our human serum 
controls; therefore, culture supernatants from paired wells were pooled immediately. The 
other plates lost binding strength after the second week and were not pursued for cloning. 
The reactive B cell clones were found on Plate 10, row G, wells 3 and 4, exhibiting 
binding levels similar to human serum controls (Figure 4.20). B cells from both wells 
were subcloned after three weeks, and the reactive well was identified as 04 (Figure 
4.21). H5 HA binding was low after subcloning but binding increased with each week. 
The identity of a H5HA-reactive clonal population is currently being pursued. The 
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Figure 4.18. Immortalized tonsil B cells (TNSL D) produce undetectable or very low 
levels of IgG that specifically binds H5 HA after one week. EBV immortalized B cells 
from TNSL D were stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab'h, 
and cultured in ten 96-well plates (1.5 x 105 cells per well). H5 HA binding was 
determined as described in materials and methods. One week later, culture supernatants 
from all wells on each plate (150~1 per well) were collected, and 50~1 per well were 
pooled and assayed for H5 HA binding as described in the Materials and Methods 
section. Significant H5 HA specific binding was not detected on any plates. Mean 
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Figure 4.19. Immortalized tonsil B cells on Plate 10 produced IgG that specifically 
binds U5 UA after two weeks of culture, from TNSL D sample. Culture supernatants 
from all wells on each plate of EBV immortalized B cells from TNSL D were pooled 
(501l1 per well) after two weeks in culture and assayed for H5 HA binding. H5 HA 
specific binding was detected on Plates 1,8,9 and 10, with highest reactivity on Plate 10. 
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Figure 4.20. H5 HA specific IgG production identified in culture supernatant from 
paired adjacent wells on row G of Plate 10, from TNSL D sample. Cultured 
supernatants from EBV immortalized B cells from TNSL D (150~.d per well) were 
collected from each well after 3 weeks of culture, and 50~1 per sample from paired 
adjacent wells on reactive Plate 10 were pooled and assayed for H5 HA binding as 
described in materials and methods. All wells were pooled and assayed on reactive Plates 
I, 8 and 9. Row G, wells 3 and 4 (green) had the highest H5 HA binding, similar to 
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Figure 4.21. Identification of H5 HA . reactive IgG in Well G4 on Plate 10, from 
TNSL D. Culture supernatants from EBV immortalized B cells from TNSL D sample 
(50~.d per well) on Plate 10, Row G, wells 3 and 4 were tested for H5 HA binding as 
described in materials and methods. Row G, well 4 (green) had the highest H5 HA 
binding and was selected for continued sub-cloning. Mean absorbance level OD405 ± SD 
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Figure 4.22. Subcloning strategy for isolating H5 HA specific B cells from TNSL D. 
EBV immortalized B cells from TNSL D were stimulated to produce IgG with CD40L, 
BAFF and anti-IgM (Fab')2, and cultured in ten 96-well plates (1.5 x 105 cells per well). 
One week later, culture supernatants from all wells on each plate (150~1 per well) were 
collected, and 50~1 per well were pooled and assayed for H5 HA binding as described in 
materials and methods. After one week, no plates had H5 HA reactive IgG. However, 
after two weeks Plates 1, 8, 9 and 10 exhibited reactivity, with Plate 10 exhibiting strong 
reactivity. Culture supernatants from paired wells on each rowan Plate 10 were pooled 
and assayed simultaneously with whole plate pools from Plates 1, 8 and 9. Paired wells 3 
and 4 in Row G on Plate 10 produced H5 HA reactive IgG and production was 
subsequently localized to well 04, which was subcloned by limiting dilution analysis into 
96-well plates containing 1, 10, 100 or 1,000 cells per well. Isolation of a single cell 
clonal population is currently ongoing. H5 HA reactivity could no longer be identified 
from Plates 1, 8 and 9 after three weeks, at which point screening was discontinued. 
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TNSL E: B cells were isolated from tonsil (Table 4.2), immortalized with EBV, 
stimulated with anti-IgM (Fab')2, CD40L and BAFF and plated in 4, 96 well plates. 
After one week, plates 1 and 3 were weakly reactive to H5 HA (Figure 4.23). After two 
weeks, plate 1, rows Band E and Plate 3, row A were identified as containing B cells that 
secreted IgG reactive with H5 HA (Figure 4.24). Plate 1, row B wells 5 and 6, row E, 
wells 3 and 4, 11 and 12; and plate 3 row A, wells 9 andIO were identified as IgG 
reactive for H5 HA (Figure 4.25). Of these paired wells Plate I row Ewell 11 and plate 
3, row A, well 10 contained reactive clones (Figure 4.26). Only Plate 3, row A, well 10 
was subcloned because it had the strongest binding and gave us the best chance of and 
finding a reactive clone. Reactivity was detected in 1000 cells/well after only five weeks 
(Figure 4.27). The scheme for identifying reactive wells and subcloning reactive B cells 
is outlined in figure 4. 27. 
Summary: H5 HA reactive B cell clones have been isolated in two (TNSL D and E) out 
of the five tonsil samples. A third tonsil sample exhibited early H5 HA reactivity, but the 
sample was lost due to fungal contamination and no clones were recovered. The results 
of the tonsil experiments are summarized in Table 4.3 Our results have indicated that our 
approach for in vitro creation of human monoclonal antibodies from tonsil and peripheral 
blood B cells against specific targets is feasible. 
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Figure 4.23. Immortalized tonsil B cells produced undetectable or very low levels of 
H5 HA reactive IgG after one week of culture, from TNSL E. EB V immortalized B 
cells from TNSL E were stimulated to produce IgG with CD40L, BAFF and anti-IgM 
(Fab')2, and cultured in four 96-well plates (105 cells per well). One week later, culture 
supernatants from all wells on each plate (150IlI per well) were collected, and 50111 per 
well were pooled and assayed for H5 HA binding as described in materials and methods. 
Significant H5 HA specific binding was not detected on any plate above negative control 
purified human IgG. Mean absorbance level OD405 ± SD of samples and controls (n=3) 
are shown. 
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Figure 4.24. U5 UA reactive IgG was detected in culture supernatants from 
individual rows on Plates 1 and 3, from TNSL E. EBV immortalized B cells from 
TNSL E were stimulated to produce IgG with CD40L, BAFF and anti-IgM (Fab'h, and 
cultured in four 96-well plates (105 cells per well). Two weeks later, culture supernatants 
from all wells on each plate (1501l1 per well) were collected and 50111 per well of each 
was pooled from individual rows on plates 1 and 3, and then tested for H5 HA binding as 
described in materials and methods. Supernatants from all wells on Plates 2 and 4 were 
pooled and simultaneously assayed. Row A of Plate 3 and Rows E and B of Plate 1 had 
significant levels of H5 HA reactive IgG, and were subjected to further analysis. Mean 
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Figure 4.25. H5 HA specific IgG production identified in culture supernatant from 
pooled adjacent wells on Plates 3, 5 and 6, from TNSL E. Week 3 culture supernatants 
from pairs of adjacent wells on Plate 1, rows Band E, and Plate 3, row A were pooled 
and assayed for H5 HA binding activity as described in materials and methods. Plate 1 
row B, wells 5 and 6; Plate 1 row E, wells 11 and 12 and 3 and 4; and Plate 3, row A, 
wells 9 and 10 exhibited H5 HA reactive IgG production and were selected for individual 
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Figure 4.26. Identification of H5 HA specific IgG production in culture supernatant 
from individual wells on reactive plates, from TNSL E. Week 4 culture supernatants 
from individual wells B5 and B6, E3 and E4, Ell and El2 on Plate I wells and wells A9 
and AIO on Plate 3, were assayed for H5 HA binding as described in materials and 
methods. Strong H5 HA binding was observed from well AIO on Plate 3, which was 
selected for subcloning. Mean absorbance levels at OD405 ± SD of samples and controls 




























Figure 4.27. Identification of H5 HA specific IgG production was identified in 
culture supernatant two weeks after sub cloning on plates containing 1,000 cells per 
well, from TNSL E. Two weeks after subcloning immortalized B cells by limiting 
dilution analysis , culture supernatants from each of the plates were pooled and assayed 
for H5 HA binding as described in materials and methods. H5 HA binding was only 
observed in supernatants from the 1,000 cells/well plate. Further subcloning analysis is 
ongoing. Mean absorbance level at OD405 ± SD of samples and controls (n=3) are shown. 
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Chapter 5: Discussion and Future Directions 
A model of in vitro B cell differentiation was created using tonsil and PBMC 
derived B cells, Epstein-Barr virus, exogenously supplied cytokines, recombinant 
costimulatory molecule soluble CD40L, and an agent that induces BCR cross linkage 
(anti-IgM (Fab')2). The aim of this model was to force B cell differentiation from mature 
naYve B cells to plasma cell stage in the absence of T cells or other cellular interactions. 
We have exploited this model to create human monoclonal antibodies in vitro for 
therapeutic use. For creation of monoclonal antibodies, two major stages were required: 
The first was optimization of EBV infection which required both viral concentration and 
"spinfection". The second step was to induce immunoglobulin isotype class switching of 
immortalized B cells using T cell derived cytokines and other signaling factors. These 
steps were optimized to immortalize the largest portion of the naYve B cell repertoire 
possible for the purpose of obtaining IgG antibodies specific to antigens of interest for 
therapeutic use. Our in vitro B cell differentiation model can be applied to the study of B 
cell differentiation, cancer, as well as Epstein-Barr virus research. In the current 
application this model was exploited to create human monoclonal antibodies that 
recognize H5 hemagglutinin (HA) of avian influenza. 
Optimization of Epstein-Barr virus infection was achieved through the 
application of several established methods for virus concentration. The first method 
attempted was TLR ligands addition, which had been shown to improve EBV infection of 
memory B cells [82]. TLR ligands mimic foreign antigens that are recognized by the 
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innate immune system through binding to TLR on the surface of immune cells. Traggiai 
et al. (2004) [82] demonstrated that the addition of CpG~ an unmethylated portion of 
DNA that activates TLR 4 and 9 [49], to their infection protocol increased EBV infection 
efficiency of memory B cells to 30-100% [82]. Primary tonsil B cells are known to 
express TLR 1,6,7,8,9 and 10, determined through northern blot analysis of primary B 
cells, and high expression of TLR 9 and 10 on activated B cells [88]. Therefore, several 
TLR ligands were analyzed for effect on EBV infection efficiency of tonsil B cells. TLR 
ligands that bind a wide range of TLRs on B cells were assayed in our infection protocol: 
Pam3, a synthetic lipoprotein mimics bacterial lipoproteins, binds TLR 2/1 [89], 
Zymosan (Zymoson), from yeast cell extracts, binds TLR 2/;, Poly I:C, Polyinosine-
polycytidylic acid, mimics double-stranded RNA of viruses, binds TLR 3; LPS, 
lipopolysaccharide from bacteria, binds TLR 4 [89]; Imiquimod, imidaoquinoline amine 
analogue to guanosine and antiviral, binds TLR 7; and epG, unmethylated DNA mimics 
bacterial DNA, binds TLR 4 and 9 and activates B cells [89]. Each of these ligands has a 
different structure and, mimics different antigen binding different TLRs on cells. In our 
hands, the addition of Imiquimod, Pam3 and epG to our infection protocol doubled 
infection efficiency to 2% (over 1 % for untreated B cell infection) (Figure 4.1 A). The 
increase observed with the addition of Imiquimod, Pam3 and epG was not unexpected 
because these TLR ligands bind TLRs expressed on primary tonsil B cells; however, the 
infection efficiency was low and varied with preparation (Figure 4.1). 
Viral infection efficiency has also been shown to be effected by viral 
concentration, a method that has been around for many years and has evolved with time. 
Sucrose gradients were first used to concentrate herpes-simplex virus 1 through overlay 
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of VIrUS on discontinuous gradients of 10%, 30% and 60% sucrose followed by 
centrifugation. Alternativly, viral supernatant was added to five ml of 250/0 sucrose 
followed by ultracentrifugation [50]. Similar methods for EBV were developed [51). 
This resulted in purified and concentrated viral stock resulting in between 50-94% 
infection. However, virus was lost at a high (>50%) rate through high speed 
ultracentrifugation. Therefore, another method for EBV concentration was tried using T-
10 dextran, where virus was overlaid onto a 5-30% continuous gradient and centrifuged 
at 76,000 xG for one hour [51]. Dextran gradients resulted in between 13 and 29% 
infectivity. Both of these methods purify viruses from cellular contaminants, but they are 
time consuming, expensive and require large quantities of virally infected cells, posing 
bio-safety hazards. Thus we pursued other options. Retroviruses have been concentrated 
by spinning viral supernatant at high speeds [40), however this will not work for less 
hearty viruses like EBV. Concentration and purification of murine leukaemia virus was 
achieved through ultrafiltration centrifugation, which increased infection efficiency 
markedly [104-106). To apply this method EBV containing supernatant was centrifuged 
over a column with a 100 Kb or larger cut-off and spun according to manufacturer's 
directions. A large molecular weight cut off was thought to be the best, since EBY is 
large compared to cellular contaminants and contaminants will be cleared quickly 
without damaging the virus. The concentrated EBV was applied as described in methods 
and increased our primary infection efficiency to 50/0 (over unconcentrated EBY at 1-2%) 
(Figure 4.1 B). 
"Spinoculation" or "spinfection" is a method that has been shown to increase 
infection efficiency of several viruses [91, 92]. In "spinfection" virus and cells are 
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combined and spun at low speeds (900-1200xG) for 1-2 hours at room temperature [91, 
92]. This method has been shown to increase the infection efficiency of Cytomegalovirus 
(CMV) and Human immunodeficiency virus (HIV) to nearly 100% and increased EBV 
infection [92, 107-109] (personal communication with David Nadal). We applied 
concentrated EBfa V -GFP to primary tonsil B cells and spun them at 900xG for 1 hour. 
After 24 hours we confirmed other reports, achieving near 100% infection efficiency of B 
cells, seen as an entire peak shift in Figure 4.3 [52]. The mechanism of how 
"spinfection" increased infection efficiency is a point of debate. Some groups have 
proposed that reversible virus binding to cells upon initial exposure was an underlying 
mechanism [107, 110]. While other groups reported that "spinoculation" increases the 
number of viruses binding to the cell surface by approximately 40% [52] resulting in 
increased infection. Also, "spinfection" may alter the fluidics in the culture [52]. All of 
these mechanisms are closely related and reasonable mechanisms for the observed viral 
infection. Optimization of EBV infection of primary B cells was a necessary first step for 
our novel method for the production of human monoclonal antibodies. 
Having optimized EBV infection of B cells, the next step was to promote the 
differentiation of the immortalized B cells in vitro. NaIve B cells are activated through 
the interaction between the BCR and antigen as well as co-stimulatory signals from T 
cells, such as CD40L and T cell derived cytokines. Current theory on EBV infection is 
that the virus exploits the antigen dependent B cell differentiation pathway and EBV 
genes may assist in this differentiation. Therefore, we postulated that we could force 
EBV immortalized LCLs to differentiate if we could supply both T cell derived growth 
factors as well as BCR cross-linkage to mimic antigen. 
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To determine our starting point for differentiation, primary B lymphocytes, prior 
to infection, were stained for common B cell markers. We found that the tonsil B cells 
have a mostly naiVe B cell surface expression pattern: CD20 and CD 19 positive, which 
are pan B cell markers, and CD30 and CD27 low, which are activation markers, and IgD 
high, which is a naive B cell marker (Figure 4.6) [53]. This indicated that we were 
starting with a mostly naIve B cell population. 
We postulated that we would be able to track differentiation through ELISA 
analysis of IgG and IgM secreted from the LCLs after treatment with the signaling 
factors. Increased IgG would be a preliminary indicator that B cells have differentiated 
and undergone Ig isotype class switching. It has been shown that IL-6 and BCR cross-
linkage of primary B cells induced the loss of IgD, indicating that the cells had been 
activated [54]. We confirmed this finding in our studies of EBV immortalized B cells of 
two tonsil samples and PBMC Al (Figures 4.5, 4.6 and 4.12). Ligation of CD40 has also 
been shown to induce terminal differentiation of naIve, memory and germinal center cells 
in vitro [113-116]. We used soluble CD40L in the presence of BAFF, which plays an 
important role in B cell development, survival, and immunoglobulin production [117], in 
addition to anti-IgM (Fab'h which cross-links the BCR to force the differentiation of 
EBV+ tonsil B cells. We confirmed these studies by demonstrating the appearance of IgG 
antibodies after two weeks of treating two tonsil samples and one PBMC sample (TNSL 
D and E, PBMC A2). Our results indicated that we could force B cell differentiation and 
isotype class switching through the addition of anti-IgM (Fab')2 and either IL-6 (Figures 
4.5, 4.6 and 4.8) or CD40L and BAFF and (PBMC A2, TNSL D and E, summarized in 
Table 4.3). 
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It has also been reported that IL-4 in combination with B cell receptor cross-
linkage and feeder cells causes primary B cell differentiation and Ig isotype class 
switching from IgM to IgE and IgG [116, 118]. However, BCR cross-linkage and IL-4 
treatment did not cause isotype class switching of EBV immortalized B cells. Instead, we 
found that IL-4 and anti-IgM (Fab')2 increased IgM secretion (Figure 4.5). All of the 
cytokine treatments tested sustained immunoglobulin secretion for many months in vitro, 
which indicated that theses cells had differentiated to plasma like cells. 
Differentiation of EBV immortalize B cells was confirmed through surface 
staining of LCLs that preferentially secreted IgG (treated with anti-IgM (Fab'h and IL-6) 
or IgM secreting cells (treated with anti-IgM and IL-4). As demonstrated in Figure 4.6, 
primary tonsil B cells were initially mostly naIve: CDI9, CD20 and IgD positive, CD27 
and CD30 negative (Figure 4.6). However, flow cytometry revealed that after treatments, 
both cell populations resembled early plasma cells: CD2010, IgDlo, CD27 and CD30 
positive [112, 119, 120). Plasma cells lose CD20, during maturation [55] and IgD is lost 
after B cells have been exposed to antigen [54]. CD27 expression was induced by BCR 
cross-linkage and maintained long-term by post-germinal center B cells [121-123]; 
CD30 expression is consistent with activated B cells [120]. Plasma cells secrete both IgM 
and secondary Ig isotypes [56], which is consistent with our findings that EBV 
immortalized, IgM secreting cells have a differentiated phenotype (Figure 4.6). The only 
difference we saw by flow cytometry between IgM and IgG secreting cells was that the 
IgG secreting cells expressed high levels of CD38, a common plasma cell and terminal 
differentiation marker [53] while high IgM secreting LCLs had very little CD38 (Figure 
4.6). Thus, our results indicated that the IgG secreting B cells had terminally 
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differentiated. Furthermore~ our results indicated that we have created a novel method for 
inducing B cell differentiation of EBV immortalized cells in vitro by using exogenously 
supplied 'cytokines, soluble CD40L and BCR cross-linkage. 
Recently it has been shown that primary, naIve B cells isolated from PBMC or 
cord blood, can be forced to differentiate and undergo isotype class switching through 
BCR cross-linking in the presence of IL-21 and CD40 ligation [57]. At this time we have 
not been able to reproduce this result in EBV immortalized B cells (data not shown), 
indicating that EBV immortalized B cells may react differently to cytokine stimulation. 
Huggins et al. (2007) found that culturing naIve (CD2710) primary B cells isolated from 
PBMC in a 3 step system induced B cell differentiation to plasma cells [58]. The 3 step 
program consists of: (I) CpG, IL-2, 10 and 15 for 4 days; (2) IL-2, IL-6, IL-I0 and IL-15 
and anti-CD40 antibodies for the next 3 days; then (3) IL-6, IL-15, lPN-a, hepatocyte 
growth factor, and hyaluronic acid for the last 3 days [58]. This method utilizes primary 
B cells that are not immortalized with EBV and requires other means to activate the B 
cells to begin differentiation. Another method involves stimulating primary B cells 
isolated from PBMC with autologous B plasmacytoid dendritic cells (PDCs) followed by 
treatment with CpG and BCR cross-linkage [127] to yield plasma cells. All of these 
methods utilize primary B cells that are not immortalized with EBV. One method 
requires a feeder population to induce differentiation as well as exogenous cytokine and 
TLR ligand addition. 
Other methods to create plasma cells in vitro have utilized pnmary germinal 
center B cells, cultured with CD40L expressing cells, and treated with IL-2 and IL-IO, 
followed by removal of CD40L after one week [59]. Other methods involved activation 
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of primary CD27+ memory B cells isolated from PBMC with CpG and IL-15 yielding 
plasma cells that secreted antigen specific antibodies [114]. These methods differ from 
our method because they rely on B cells that have already begun the differentiation 
process, which can lead to less stringent activation requirements than naIve B cells. This 
method also uses primary B cells that are not immortalized with EBV, which could alter 
reacti vity as well. 
It has also been found that culturing primary tonsil B cells with synoviocytes 
induced plasma cell differentiation, and lead to high immunoglobulin expression [129]. 
NaIve and memory B cells isolated from PBMC that were cultured with CD32 
transfected mouse fibroblasts coated with anti-CD40 and treated with and IL-4 followed 
by IL-2, IL-3, and IL-I0 [60] differentiated to plasma cells in vitro. However, in this 
system, memory B cells secreted IgG and naiVe B cells differentiated but did not undergo 
isotype class switching to secrete IgG. This differed from our method, which has the 
capability to force the differentiation and Ig isotype class switching to obtain IgG 
antibodies. 
Primary memory B cells isolated from PBMC and tonsils can be induced to 
plasma cells through BCR cross-linkage and CD27 ligation with CD70. These cultures 
also require the addition of IL-2, IL-4, and IL-I0 [130, 131]. Therefore, our method for 
B cell differentiation is superior because we can induce differentiation of nai"ve B cells. 
VH4-34 positive memory and naIve B cells cultured with irradiated CDl54-transfected 
mouse fibroblasts and treated with CD70, IL-2 and IL-I0 underwent differentiation and 
became antibody producing plasma cells [61]. This method required that a certain subset 
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of B cells be used, limiting the use of this method for antibody production. Our method 
was not restricted to a certain subset of B cells and could be applied to all naIve B cells. 
Traggiai et al (2004) [82] has created a method for human monoclonal antibody 
production through the immortalization of memory B cells from PBMC of SARS 
recovered volunteers. The EBV infected memory B cells were first obtained from 
mononuclear cells, and then treated with CpG to achieve IgG secreting plasma cells. 
Simmons et al. (2007) [62] has performed a similar study in H5Nl recovered patients. 
PBMC derived memory cells from avian influenza patients were isolated and 
immortalized with EBV in the presence of CpG. Memory B cells secreting antigen 
specific antibodies were isolated. Our method is similar to these methods because both 
utilize EBV immortalized B cells to create plasma cells that will proliferate indefinitely 
in vitro. Our method is different because we did not start with memory cells, but instead 
forced B cell differentiation in vitro with external stimulation. Our method also does not 
require that the B cells be isolated from a pathogen exposed individual, increasing the 
availability of donors. 
Our novel method for in vitro induction of B cell differentiation using EBV, BCR 
cross-linkage, and soluble CD40L has been demonstrated to work in several tonsil B cell 
samples (Figure 4.5, TNSL, A, D and E). We showed that we could induce production of 
IgG antibodies specific for H5 hemagglutinin in tonsil B cells from healthy children not 
known to be exposed to H5N 1 avian influenza. Our in vitro model of EBV+ B cell 
differentiation can be applied in many research fields: Epstein-Barr virus infections, B 
cell differentiation, and EBV positive B cell lymphogenesis (e.g. development of 
91 
Burkitt's and Hodgkin's lymphoma), possibly leading to a new understanding and 
possibly cancer therapies. 
To test our hypothesis that we could exploit EBV immortalized B cell repertoires 
for production of antibodies of therapeutic interest, we examined the serum of healthy 
adult volunteers that had not been exposed to avian influenza, for IgG and IgM antibodies 
for reactivity with H5 HA. It is possible that any healthy individual may have antibodies 
that cross react with H5 HA. We found that 4 out of 5 volunteers (Figure 4.7) produced 
IgG antibodies that bound H5 HA. We could not determine whether there was H5 HA 
specific IgM because background IgM binding was so high that it interfered with the 
ELISA analysis. The finding of H5 HA reactive IgG antibodies in the serum could be 
interpreted to mean either that exposure to other flu strains might have resulted in an 
immune response that was cross-reactive with avian influenza H5 HA [132]. It has been 
found that immunity to influenza virus can influence later viral infection through altering 
cytokine profiles[63]. The altered immune response might inhibit illness from other viral 
infection or enhance or decrease mononuclear responses [63]. Thus, it has been shown 
that heterologous immunity occurs between viruses resulting in altered protective 
immunity [63]. For example, Clute et al (2005) [132] found that some EBY+ 
mononucleosis patients have activated T cells specific for herpesviruses other than EBY, 
indicating that closely related viruses may result in cross-reactive immune responses. 
These findings allowed us to entertain the possibility that we could isolate B cells that 
cross react with H5 HA from previously unexposed individuals. 
The H5 HA ELISA that we developed was sensitive enough to detect IgG 
antibodies, but not IgM antibodies in human serum. A H5N 1 avian influenza virus 
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capture based ELISA has been developed USIng mouse monoclonal antibodies that 
recognize H5 HA [64]. Monoclonal antibodies were bound to the plate then H5 HA was 
added and human sample was layered on top, then detected with goat anti-human 
antibodies. In comparison, the ELISA we developed had the capability to detect H5 HA 
reactive IgG antibodies in serum and in cell supernatants in fewer steps. On the other 
hand, the IgM ELISA we created was not able to detect H5 HA specific IgM due to high 
background binding. This could happen because IgM is inherently sticky, meaning that 
recognition of antigen is less stringent than IgG antibodies. A capture based ELISA 
where mouse anti-H5 HA is bound to the plate, then H5 HA is applied, followed by 
sample supernatant and detection with a goat anti-human IgM antibody, might fix the 
problem. The samples for the IgM ELISA could also be diluted or the percentage of BSA 
could be increased in the block, to prevent non-specific binding. 
H5 HA specific IgG producing B cells from healthy volunteers, were isolated 
from both PBMC and tonsil samples. B cells were subjected to EBV infection and 
differentiation. We were able to identify H5 HA IgG antibodies in the culture supernatant 
from 1 (Figure 4.8 and 4.13) out of 2 healthy volunteers after two weeks of cytokine and 
signaling agent treatments, possibly indicating that IgG producing B cells were not 
originally in the culture and class switching had occurred. Identification of H5 HA 
reactive IgG secreting B cells correlated with detection of IgG antibodies in the serum of 
the individual. Serum concentration of H5 HA specific IgG from PBMC Al and A2, had 
a high level of binding, while serum from PBMC B had no detectable binding. This could 
also indicate that we immortalized memory B cells in the periphery from PBMC A that 
cross-reacted with H5 HA. 
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We repeated these experiments in tonsil (TNSL) samples to gain access to a larger 
naIve B cell repertoire. Four tonsil samples (TNSL B, C, D and E) were treated with anti-
IgM (Fab')2, CD40L and BAFF, which resulted in the production of H5 HA reactive IgG 
producing B cells that could be subcloned in 2 out of the 4 tonsil samples. A fifth tonsil 
sample (TNSL A), treated with anti-IgM (Fab')2 and IL-4, also had H5 HA reactive IgG 
(Figure 4.15), but was lost to fungal contamination and was not subcloned. For all 
positive samples (TNSL A, D, E) H5 HA reactive IgG was detected at acceptable levels 
only after two weeks of cytokine treatments (Figures 4.15, 4.22 and 4.28, Table 4.3), 
consistent with induction of Ig isotype class switching between weeks 1 and 2. Thus, 
overall we were able to identify H5 HA reactive IgG in approximately half of the TNSL 
samples tested (3 out of 5), and H5 HA reactive B cells were subcloned from 2 out of 3. 
Other studies on cross-reactivity of viral antibodies, have found that not all study 
volunteers have EBV reactive antibodies that react with other herpesviruses [132]. 
Therefore, some volunteers will not have B cell repertoires that produce antibodies 
specific for H5 HA. 
Our method of non-specifically inducing B cell differentiation has allowed us to 
isolate H5 HA specific IgG secreting B cell clones repeatedly in PBMC samples and two 
TNSL samples (Table 4.3). On the other hand, we failed to recover H5 HA-reactive B 
cells in two tonsil (TNSL B and C) samples that exhibited very low level H5 HA 
reactivity after one week in culture, (Figure 4.16 and 4.17) but, by the second week, the 
initial faint binding had been reduced and no reactivity was recovered. The disappearance 
of the initial faint, positive signal could indicate two things; either our ELISA gave false 
positive signals or that the reactive B cells died. Either way, testing of week one culture 
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supernatants was unreliable, while positive results from week two supernatants were 
consistently reliable. Even with the failure to get reactive clones in two samples, our 
results indicate that we have created a novel approach for the production of human 
monoclonal antibodies in vitro. 
Our novel method of antibody creation is different is from all other human 
monoclonal antibody production techniques. Technology has come a long way since the 
first monoclonal antibodies were produced in animals. Those animal derived 
monoclonals were not useful for therapeutics because they resulted in serum sickness [77, 
78]. Phage display technology has sped up screening of antibodies [25] but, the resulting 
antibodies were often of low affinity. Jones et a1. (1986) created a technique for the 
productions of human monoclonal antibodies from mouse antibodies through substitution 
of the complementarity-determining regions (CDR) [35] which elicits the serum sickness. 
CDR replacement offered a different way of constructing human monoclonal antibodies 
from corresponding mouse monoclonal antibodies. Our method is simpler and B cells 
secreting antibodies of therapeutic interest can be identified by ELISA within a few 
weeks of sample collection. Furthermore, the antibodies are entirely of human origin. 
Another method for human monoclonal antibody production is the use of 
XenoMouse technology [34] where mice express human immunoglobulin Ig genes 
replacing the mouse Ig genes. Like CDR replacement, the humanized mice retain the ease 
of generating mAbs from a mouse but avoid serum sickness and cloning. These 
monoclonal antibodies from XenoMouse mice exhibit therapeutic potential both in vitro 
and in vivo [34]. So far, humanized mice has proven to be a good approach for producing 
antibodies; however, these mice are not available to the general public for mass 
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production of antibodies. These constraints on current methods for the creation of 
monoclonal antibodies create a need for a novel technique like ours that is relatively rapid 
and cost effective. 
Recently, a new method for creating human monoclonal antibodies in vitro has 
been reported [82, 83]. This method utilizes Epstein-Barr virus (EBV) infection of 
peripheral blood memory B cells from volunteers that have been exposed to and 
recovered from pathogen infection [82, 83]. EBV was used to transform human memory 
B cells to examine the B cell repertoire of donors that have recovered from SARS-Co V 
and H5N 1 avian influenza virus infection [82, 83]. This method is limited because the B 
cells must come from a donor that has already cleared an infection. This method would 
not work for deadly pathogens like Ebola because donor availability becomes a problem, 
and volunteer exposure is extremely hazardous and unethical [36]. Our method is 
advantageous to these EBV immortalization methods because it does not require that the 
donors were initially exposed to harmful pathogens. 
A downfall of our method was that binding of H5 HA antibodies sometimes 
decreased after subcloning, and in some cases the activity was lost. It has been noted in 
the literature that genomic instability, chromosomal aberrations, aneuploidy and eventual 
loss of cell function can result from EBV immortalization [135, 136]. Aneuploidy is a 
state in which the wrong number of chromosomes impairs cellular function. This could 
result in loss of IgG secretion and slowed cellular growth. We plan to side step this 
problem through faster identification and screening of H5 HA reactive B cells. We will 
then clone out the variable region from the isolated B cells and transfect myeloma cell 
lines for production of H5 HA specific immunoglobulin. 
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Future directions 
We have identified B cell clones that secrete IgG that binds HS HA; we plan to 
analyze, these cells for somatic hypermutation. Somatic hypermutation is indicative of 
affinity maturation. B cell clones will be sequenced and compared to germ line sequences 
from the same donor to determine if somatic hypermutation of the variable region has 
occurred. We can also look by PCR, at B cells frozen at one week after immortalization 
to compare the sequences. 
We also plan to create more HS HA specific B cell clones through antigen 
specific B cell differentiation. We will link H5 HA to beads, then when an antibody 
recognizes and binds HS HA, the beads will cross-link the B cell receptor. This would 
lead to antigen specific B cell differentiation. This method has successfully been used in 
vitro to create antigen specific polyclonal antibody reaction [65]. This method could 
potentially yield higher affinity HS HA-specific clones. 
The antibody repertoire that we have created must be tested in in vitro 
neutralization of HSN 1 and other flu strains on MDCK cells to determine if they have 
therapeutic potential. These assays will be performed in the BSL 3 laboratory following 
World Health Organization methods [138]. HSN 1 neutralizing antibodies will then be 
examined for epitope mapping and variable regions of these antibodies will be sequenced 
for future reference. Non-neutralizing antibodies might still be useful for diagnostic 
purposes. 
The identification of HS HA reactive antibodies from tonsil samples has many 
implications for monoclonal antibody production. The first is that this technology can be 
applied to create antibodies specific for many different antigens, including soluble tumor 
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antigens and other viruses, not just avian influenza. Since our process is performed in 
vitro using EBV immortalized human B cells, it has the capacity to be rapid and cost 
effective. B cells that secrete antigen specific IgG can be frozen for long-term storage 
and can later be grown up quickly as needed. 
In summary, we have provided evidence that we can isolate, immortalize and 
induce Ig isotype class switching of tonsil B cell and furthermore isolate B cells secreting 
IgG of interest. We have also shown that this technology can be used to create human 
monoclonal antibodies in vitro that are specific for H5 hemagglutinin (HA). We propose 
that with further verification of this technology, it might be applied to the creation of 
antibodies specific for other antigens of therapeutic interest. 
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